



ONKOLOŠKI
INŠTITUT
LJUBLJANA



INSTITUTE
OF ONCOLOGY
LJUBLJANA

EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY

Rak v Sloveniji

2013

Cancer in Slovenia



Rak
v Sloveniji

2013

Cancer
in Slovenia

Naslov / Title

Rak v Sloveniji 2013 / Cancer in Slovenia 2013

Uredniški odbor / Editorial Board

Vesna Zadnik, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Katja Jarm,
Vera Pompe-Kirn, Maja Primic Žakelj,
Primož Strojman, Branko Zakotnik in Tina Žagar

Računalniška obdelava / EDP analysis

Tina Žagar in Katarina Lokar

Oblikovanje in priprava za tisk / Design & Typesetting

Studio N, studio za oblikovanje in grafično pripravo, Ljubljana

Tisk / Printing

Grafika Gracer d.o.o., Celje

Izdajatelj / Published by

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia

Naklada / Published in

500 izvodov / 500 copies

Nasvet za citiranje / Recommended reference

Rak v Sloveniji 2013. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2016.
Cancer in Slovenia 2013. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2016.

Osebe Registra raka Republike Slovenije / Staff of the Cancer Registry of Republic of Slovenia

Maja Primic Žakelj, vodja / head
Barbara Babuder, Andrej Kirn, Andrej Krašovec, Darja Strle, Fani Škrlec, Nataša Šturm in
Tina Žagar

Naslov / Correspondence to

Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:
<http://www.onko-i.si/rrs/> <http://www.slora.si/>
<http://www.onko-i.si/crs/> <http://www.slora.si/en/>

Uvod	6
Viri podatkov in metode registracije	8
Viri podatkov	8
Priprava podatkov za računalniško obdelavo	9
Kakovost podatkov RRRS in popolnost registracije	10
Statistične metode	11
Incidenca in umrljivost	11
Grobe in starostno specifične stopnje	11
Starostno standardizirane stopnje	11
Kumulativne incidenčne stopnje in kumulativno tveganje	12
Prevalenca	12
Relativno preživetje	13
Prebivalstvo Slovenije	14
Rak v Sloveniji 2013	15
Zahvala	18
Introduction	19
Data sources and methods of registration	21
Data sources	21
Preparation of data for computer processing	22
Data quality and completeness of registration	23
Statistical methods	24
Incidence and mortality	24
Crude and age-specific rates	24
Age-standardised rates	24
Cumulative incidence rate and cumulative risk	25
Prevalence	25
Relative survival	26
Population of Slovenia	27
Cancer in Slovenia 2013	28
Acknowledgment	31
Reference / References	32

Slike / Figures

Slika 1:	Breme raka, Slovenija 2013.	34
Figure 1:	Cancer burden, Slovenia 2013.	
Slika 2:	Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2013.	34
Figure 2:	Percentage distribution of all cancer sites by age group and by sex, Slovenia 2013.	
Slika 3:	Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2013.	35
Figure 3:	The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2013.	
Slika 4:	Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2013.	36
Figure 4:	Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2013.	
Slika 5:	Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2013.	37
Figure 5:	Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2013.	
Slika 6:	Petletno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2004–2008 in 2009–2013 po spolu.	38
Figure 6:	Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2004–2008 and 2009–2013 by sex.	
Slika 7a:	Tabela incidence in grobe incidenčne stopnje redkih, pogostih in nerazvrščenih rakov, Slovenija 2004–2013.	41
Figure 7a:	Table of incidence and crude incidence rate of rare, common and unclassified cancers, Slovenia 2004–2013.	
Slika 7b:	Redki raki razporejeni v 15 skupin, Slovenija 2004–2013.	44
Figure 7b:	Rare cancers categorized in 15 groups, Slovenia 2004–2013.	
Slika 7c:	Število skupin redkih rakov glede na grobo incidenčno stopnjo, Slovenija 2004–2013.	44
Figure 7c:	Number groups of rare cancers by crude incidence rate, Slovenia 2004–2013.	
Slika 7d:	Odstotni delež redkih, pogostih in nerazvrščenih rakov po starostnih skupinah, Slovenija 2004–2013.	45
Figure 7d:	Percentage distribution of rare, common and unclassified cancers by age group, Slovenia 2004–2013.	
Slika 7e:	Groba letna incidenčna stopnja redkih, pogostih in nerazvrščenih rakov, Slovenija 2004–2013.	45
Figure 7e:	Crude annual incidence rates of rare, common and unclassified cancers by age group, Slovenia 2004–2013.	

Podatki v tabelah / Data in tables

Tabela 1:	Opazovana in ocenjena incidenca raka, Slovenija 2004–2013 in 2016.	46
Table 1:	Observed and estimated cancer incidence, Slovenia 2004–2013 and 2016.	
Tabela 2:	Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2013.	47
Table 2:	Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2013.	
Tabela 3:	Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2013.	48
Table 3:	Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2013.	
Tabela 4:	Incidenca raka po lokaciji, spolu in starosti, Slovenija 2013.	52
Table 4:	Cancer incidence by site, by sex and by age, Slovenia 2013.	

Tabela 5:	Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2013.	56
Table 5:	Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2013.	
Tabela 6a:	Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2013.	62
Table 6a:	Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2013.	
Tabela 6b:	Starostno standardizirana incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2013.	63
Table 6b:	Age standardised incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2013.	
Tabela 7:	Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2013.	64
Table 7:	Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2013.	
Tabela 8:	Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2013.	73
Table 8:	Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2013.	
Tabela 9:	Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2013.	76
Table 9:	Incidence of non-Hodgkin's malignant lymphomas by site, by sex and by age, Slovenia 2013.	
Tabela 10:	Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2013.	77
Table 10:	Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2013.	
Tabela 11a:	Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2013, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani.	79
Table 11a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2013, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.	
Tabela 11b:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2013, ki so bili v okviru prvega zdravljenja operirani, po lokaciji raka in bolnici posega.	80
Table 11b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2013, that were treated by surgery during their first treatment by primary site and treatment institution.	
Tabela 11c:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2013, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po lokacijah raka in bolnici posega.	81
Table 11c:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2013, that were treated by systemic therapy during their first treatment by primary site and treatment institution.	
Tabela 12:	Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2013.	82
Table 12:	Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2013.	
Tabela 13:	Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2013.	83
Table 13:	Cancer mortality by site, by sex and by age, Slovenia 2013.	

Izbor publikacij / Selected publications	86
--	----

Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka materničnega vratu* (Register ZORA) in od leta 2007 *informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk* (Register DORA).

Podatki o novih primerih raka, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje državnega programa obvladovanja raka (DPOR) na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnične zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 leti do 3. V poročilih pa zadnja leta objavimo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2016); izračunana je s posebno statistično metodo za napovedovanje incidence raka.

RRRS je prva letna poročila izdal v letih 1953–1957 za leta 1951–1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957–1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom *Rak v Sloveniji* (1965–1977 in 2007–2013), v vmesnem obdobju (1978–2006) pod imenom *Incidenca raka v Sloveniji*, in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978–1987*, *Preživetje bolnikov z rakom v Sloveniji 1963–1990*, *Preživetje bolnikov z rakom v Sloveniji 1983–1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih in v deseti elektronski verziji knjige *Rak na petih kontinentih* (*Cancer Incidence in Five Continents*), ki jo izdaja Mednarodna agencija za raziskovanje raka, in v podatkovnih zbirkah *ECO*, *GLOBOCAN* in *ACCIS*.

Preživetje slovenskih bolnikov je obdelano v mednarodnih raziskavah *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *CONCORD-1*, *CONCORD-2*, *RARECARE* in *EUNICE*.

Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Od takrat deluje tudi *interaktivni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbirata RRRS do zaključenega leta obdelave, trenutno 2013 (incidenca, prevalenca in preživetje), in Nacionalni inštitut za javno zdravje RS (umrljivost). S hitrim dostopom do tujih baz omogoča tudi primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in v svetu. Dodane so tudi obširne strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka.

Viri podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00 in št. 47/15). Osnovni vir podatkov so *prijavnice rakave bolezni*. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje.

S prijavicami zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Dodatni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Nacionalni inštitut za javno zdravje RS. Veliko časa porabimo za poizvedbe o bolnikih, za katere nimamo popolnih podatkov ali pa dobimo o njih prvo informacijo šele ob smrti.

Za izračun preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %.

Pri analizi prostorske razporeditve raka upoštevamo Uredbo o standardni klasifikaciji teritorialnih enot – SKTE (2000), ki predpisuje delitev slovenskega ozemlja na 11 ravni. Točno opredeljevanje stalnih naslovov bolnikov z rakom nam omogoča redna povezava z Registrom prostorskih enot Geodetske uprave RS. V Tabeli 6 smo do Letnega poročila 2002 prikazovali podatke po 9 zdravstvenih regijah, v skladu z omenjeno uredbo pa smo potem prešli na raven SKTE-3, na 12 statističnih regij.

Slovenske statistične regije



Priprava podatkov za računalniško obdelavo

Podatke, prispele v RRRS na prijavnica, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94.

Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri malignomih krvotvornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se večja tudi število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfatičnega tkiva glede na imunofenotip, genetske spremembe in klinično sliko. Leta 2008 je bila ta klasifikacija posodobljena in v kliniki zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011). V Tabeli 10 razvrščamo neoplazme limfatičnega tkiva tudi v skladu z verzijo 2008 klasifikacije Svetovne zdravstvene organizacije.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev pri solidnih tumorjih praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem

vratu, materničnem telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor. V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah (npr. FIGO pri ginekoloških tumorjih), če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Pri kožnem melanomu zabeležimo tudi globino invazije po Clarku in debelino po Breslowu.

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka opredeljujejo naslednji kazalniki: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno.

Incidenca in umrljivost

Incidenca in *umrljivost* pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za *oceno incidence* v letu 2016 (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Pri časovnih trendih smo ocenjevali delež letne spremembe z Joinpoint regresijsko analizo. Uporabili smo program Joinpoint Regression Program (Version 4.1.1 – August 2014), ki je narejen na podlagi metodologije, ki so jo razvili Kim s sodelavci.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunano na 100.000 oseb opazovane populacije, *groba umrljivostna stopnja* pa število vseh umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so na začetku tega obdobja izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 oseb-let. *Starostno specifična stopnja* pove to relativno število (incidenčno oz. umrljivostno stopnjo) v posamezni petletni starostni skupini.

Starostno standardizirane stopnje

Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, pri kateri predpostavimo, da je starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli 2 prikazujemo poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji, še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi

regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše.

Kumulativne stopnje in kumulativno tveganje

Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču Tabele 5) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4.

Kumulativno tveganje (KT) je verjetnost posameznika, da zbolí za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100 (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojk pri ženskah 7,6/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 8,0-odstotno. To pomeni, da bo 7,6 % deklic (ali približno ena od 13), rojenih leta 2013, do 74. leta starosti verjetno zbolelo za rakom dojk.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih bolezni.

Relativno preživetje

Relativno preživetje je približek preživetja bolnikov v primeru, da bi kot vzrok smrti upoštevali samo izbranega raka. Izračuna se kot razmerje med opazovanim preživetjem proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki. Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. Izračunano je s knjižnico *relsurv* v programskem paketu R.

Opozarjamo še, da metoda, uporabljena za izračun relativnega preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati relativno preživetje na spletnem portalu SLORA. Za izračun relativnega preživetja na spletišču SLORA je uporabljena t.i. Hakulinenova ali popolna metoda izračuna relativnega preživetja. Po tej metodi prispevajo bolniki, ki jim zaradi predhodnega zaključka opazovanja ne sledimo polni čas, k relativnemu preživetju samo leta, za katera so dejanski podatki na voljo. Tako skupina zbolelih tri leta pred zaključkom opazovanja prispeva k eno- in triletnemu relativnemu preživetju, k petletnemu pa ne.

Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 1. julij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2013 so v spodnji tabeli.

Starostna skupina	Skupaj	Moški	Ženske
0–4	110.838	57.037	53.801
5–9	97.105	49.723	47.382
10–14	91.345	47.233	44.112
15–19	97.464	50.095	47.369
20–24	114.245	58.843	55.402
25–29	138.064	71.977	66.087
30–34	154.728	81.193	73.535
35–39	154.587	80.990	73.597
40–44	146.358	75.942	70.416
45–49	156.067	79.335	76.732
50–54	152.979	77.831	75.148
55–59	152.262	77.131	75.131
60–64	137.213	68.436	68.777
65–69	97.548	46.057	51.491
70–74	90.611	40.235	50.376
75–79	73.234	29.374	43.860
80+	94.466	28.226	66.240
Skupaj	2.059.114	1.019.658	1.039.456

Statistična regija	Skupaj	Moški	Ženske
Pomurska	117.675	57.624	60.051
Podravska	322.748	159.897	162.851
Koroška	71.945	36.112	35.833
Savinjska	260.479	130.139	130.340
Zasavska	43.341	21.234	22.107
Spodnjeposavska	70.860	35.655	35.205
JV Slovenija	141.989	71.361	70.628
Osrednjeslovenska	542.447	265.100	277.347
Gorenjska	203.926	100.829	103.097
Notranjsko-Kraška	52.531	26.499	26.032
Goriška	119.019	59.390	59.629
Obalno-Kraška	112.154	55.818	56.336
Slovenija	2.059.114	1.019.658	1.039.456

Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2013.

Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji.

Prebivalci Slovenije po statističnih regijah in spolu na dan 1. 7. 2013.

Leta 2013 je v Sloveniji za rakom zbolelo 13.717 ljudi, 7.442 moških in 6.275 žensk. (*Slika 1*), umrlo pa 6.071 ljudi, 3.392 moških in 2.679 žensk. Od rojenih leta 2013 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (*Tabela 5*).

Konec decembra 2013 je živel 94.073 ljudi (41.607 moških in 52.466 žensk), ki so kadar koli od ustanovitve RRRS zboleli za rakom (*Slika 1*). Ocenjujemo, da je leta 2016 za rakom zbolelo približno 14.800 prebivalcev Slovenije, približno 8.300 moških in 6.500 žensk. Ocene incidence za posamezne lokacije raka so prikazane v *Tabeli 1* skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje.

Ogroženost z rakom se zmerno večja in je največja v starejših letih; od vseh bolnikov z rakom je leta 2013 kar 61 % moških in 58 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka (*Slika 2*). Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo.

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v *Tabeli 2* poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo uporabili tri standardne populacije svetovno, evropsko in slovensko.

Pet najpogostejših vrst raka pri nas – kožni (razen melanoma), rak prostate, debelega črevesa in danke, dojke in pljuč – obsega 59 % vseh novih primerov rakavih bolezni (*Slika 3*). Raki teh organov so povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač, zato je ogroženost z njimi treba zmanjšati z ukrepi primarne preventive. Pri moških je bil z 20,0 % vseh novih primerov na prvem mestu rak prostate. Pri ženskah je bil na prvem mestu kožni rak (brez melanoma), ki je predstavljal petino primerov vseh rakov pri ženskah (21,3 %) (*Slika 3*).

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 700 % pri moških in za 470 % pri ženskah; v zadnjih 10 letih se je pri moških večala povprečno za 2,8 % letno, pri ženskah pa za 1,6 %. Groba umrljivostna stopnja se je v zadnjih 10-ih letih večala pri moških povprečno za 1,5 % letno, pri ženskah pa za 1,7 % (*Slika 4*). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna incidenčna stopnja se je v zadnjih 10-ih letih pri moških večala v povprečju le za 0,9 % letno, pri ženskah pa za 0,6 %. Kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (*Slika 4*), pri moških za 1,8 % letno, pri ženskah pa za 1,0 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi in/ali živi z rakom, medtem ko jih je prej več umrlo zaradi rakave bolezni. Vse povprečne letne spremembe, razen pri kumulativni incidenci pri ženskah, so statistično značilne pri stopnji tveganja 0,05.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 85/100.000, v zadnjih desetih letih se postopno manjša

(za 1,3 % povprečno letno), strmo pa pljučnega raka prehitelata rak prostate (povečanje za 6,3 % povprečno letno) in kožni nemelanomski rak (povečanje za 5,7 % povprečno letno). Izjemno povečanje incidence raka prostate v zadnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. Tudi časovne spremembe v pojavljanju raka debelega črevesa in danke je potrebno ocenjevati z upoštevanjem sprememb v diagnostiki – leta 2009 smo namreč v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki (SVIT). Incidenca raka debelega črevesa in danke se je pri moških med leti 2004 in 2010 povečevala za 5,3 % letno, od leta 2011 do 2013 pa pada za 10,5 % letno. Pri ženskah se večajo incidenčne stopnje raka dojk (za 1,3 % povprečno letno), kože, razen melanoma (povečanje za 4,2 % povprečno letno), pljučnega raka (za 3,9 % povprečno letno). V zadnjem desetletju se skoraj ne spreminja incidenčna stopnja raka materničnega telesa, medtem ko se incidenčna stopnja raka materničnega vratu od uvedbe Državnega presejalnega programa za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu (ZORA) strmo manjša (za 5,0 % povprečno letno v zadnjih desetih letih). Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa SVIT spreminja časovni trend pojavljanja raka debelega črevesa in danke – med leti 2004 in 2010 se je incidenca povečevala za 3,6 % letno, od leta 2011 do 2013 pa pada za 6,4 % letno. Povprečne letne odstotne spremembe so prikazane ob krivuljah na *Sliki 5*.

Slika 6 prikazuje petletno relativno preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2009–2013 po spolu in za oba spola skupaj. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2004–2008). Pri moških se je skupno preživetje povečalo za 6 odstotnih točk, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je preživetje bolnikov, zbolelih v zadnjem obdobju, večje za skoraj 4 odstotne točke. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Preživetje bolnic, zbolelih v obeh petletnih obdobjih, se ni bistveno spreminjalo in tako ostaja 59 %.

Posebno pozornost smo v letošnjem poročilu posvetili **redkim rakom**. Definicijo in njihove breme v Sloveniji povzemamo v *Slikah 7a–7e*. Za razliko od ostalih redkih bolezni, kamor uvrščamo vse bolezni s prevalenco manjšo od 50 na 100.000, so se strokovnjaki Evropske zveze, združeni v projekt RARECARE (www.rarecare.eu), zedinili, da za redke rake veljajo tisti, katerih groba incidenčna stopnja je manjša od 6/100.000 prebivalcev. V skladu s to definicijo je med redke uvrščenih 198 rakov, ki so zaradi preglednosti razvrščeni v 65 skupin, za potrebe nekaterih grafičnih prikazov pa še v 15 večjih skupin. Skupaj so redki raki v Sloveniji v deset-letnem obdobju 2004–2013 predstavljali več kot 22 % od vseh novo ugotovljenih primerov raka – letno je za njimi zbolelo okrog 2.880 bolnikov (142/100.000). Za njih je značilno, da se v primerjavi s pogostejšimi raki večkrat pojavljajo pri otrocih in mladostnikih. Kot pri vseh redkih boleznih so tudi pri redkih rakih težave podobne: pozno in težko jih diagnosticirajo, njihov nastanek in možnosti zdravljenja so slabo raziskani ali pa najustreznejše zdravljenje ni dostopno. Da bi uspešno obvladovali redke rake je pomembno, da breme teh bolezni natančno spremljamo, ter da vse

države sprejmejo smernice in določijo referenčne centre za diagnostiko in zdravljenje teh bolnikov.

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2013 pri 94,0 % od 13.717 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 5,7 % z drugimi preiskavami, le 0,3 % primerov pa je bilo v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti. Ta zadnja odstotna vrednost, ki je že več let podobna, odseva število bolnikov, ki verjetno zaradi starosti ali napredovale bolezni niso bili zdravljeni v bolnišnici. Iz *Tabele 3* je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih mestih raka, v *Tabeli 4* je prikazano razporejanje teh primerov po 5-letnih starostnih skupinah, v *Tabeli 5* pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev.

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembna za načrtovanje zdravstvenih zmogljivosti. Starostno standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v starostni strukturi prebivalcev.

Kakšna je bila morfološka slika malignomov pri 12.897 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej prikazani primeri, ki so potrjeni histološko (95 %), in tisti, ki so bili potrjeni samo citološko (5 %).

Tabela 8 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno z operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen.

Tabela 9 kaže starostno porazdelitev ektranodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ektranodalnih lokacij majhno, so prikazane le absolutne številke.

V *Tabeli 10* je prikazana porazdelitev neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, ki jo uporabljajo kliniki in patologi.

Tabela 11 prikazuje osnovne podatke o zdravljenju bolnikov; Objavljamo le podatke o prvem kurativnem zdravljenju. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz *Tabele 11a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 11b in 11c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.

Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2013. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco.

V *Tabeli 13* so uradni podatki o umrljivosti za rakom v letu 2013; zbira jih Nacionalni inštitut za javno zdravje RS. Grobe in starostno standardizirane stopnje so na voljo na spletišču Slora.

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za RRRS nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki.

Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta Ljubljana, Maruška Ferjančič in Polona Škulj.

Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Nacionalnega inštituta za javno zdravje RS in Statističnega urada RS.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor

Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the CRRS has been merged with the Unit of Epidemiology into a single Epidemiology and Cancer Registry service. Besides the CRRS, the new service also comprises the *hospital-based Cancer Registry* of the IO, which contributes a considerable part of information to the CRRS and facilitates a more detailed overview of patients treated at the IO, irrespective of their permanent residence. In the last decade, a new *national registry in charge of coordinating and monitoring the organised cervical cancer screening programme* (Registry ZORA) has been established, while an *information system to support organized breast screening program* has been established in 2007 (Registry DORA).

The data on cancer collected by the CRRS, incidence, survival and prevalence, serve together with mortality data collected by the National Institute of Public Health of RS as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of the National Cancer Control Plan (NCCP), in the field of primary and secondary prevention, diagnostics, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentric studies and for evaluation of effectiveness of cancer screening programs.

The Annual Reports of the CRRS are one of the regular ways of disseminating information on cancer among professionals and other interested groups. As we are limited by the technology of data collection from a variety of sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usually takes two to three years. Over the last few years the estimated numbers and rates for the expected incidence in the year the Annual Report is published (in this report for the year 2016) are presented; they are calculated by a special statistical method.

The first annual reports of the CRRS for the period 1951–1955 were issued during the years 1953–1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957–1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by the World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, entitled *Cancer in Slovenia* in years 1965–1977 and 2007–2013, and *Cancer Incidence in Slovenia* in the period 1978–2006. Besides Annual Reports, four special publications have been published: *Atlas of Cancer Incidence in Slovenia 1978–1987*, *Cancer Patients' Survival in Slovenia 1963–1990*, *Cancer Patients' Survival in Slovenia 1983–1997* and *Survival of Cancer Patients, diagnosed in 1991–2005 in Slovenia*. The list of other relevant publications in last five years is at the end of this report.

Data of the CRRS are included in several international databases and projects. They have been published in all nine volumes and the tenth electronic version of the

Cancer Incidence in Five Continents issued by the International Agency for Research on Cancer. The data are included in international databases *ECO*, *GLOBOCAN* and *ACCIS*. The survival of Slovenian cancer patients is analysed in the international studies *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *CONCORD-1*, *CONCORD-2*, *RARECARE* and *EUNICE*.

In 2010, the CRRS's database has been upgraded and data processing modernized. At the same time an interactive web portal named SLORA was launched as well. The name comes from the first letters of the sentence in Slovenian language: "SLOvenia and RAK/cancer". It is available at www.slora.si/en/. It enables a simple access to data on cancer in Slovenia collected by the CRRS (incidence, prevalence and survival; currently till 2013) and the National Institute of Public Health of Republic of Slovenia (RS) (mortality) as well as the comparisons with other countries in the European Union and in the world. It describes the data and offers its users professional explanations of cancer risk factors, screening and early detection and treatment outcomes.

Data sources

Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00 and 47/15). The main sources of data are *notifications of cancer*, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment.

The data gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Additional sources of information are death certificates that we get from National Institute of Public Health of RS. Where patients' data are incomplete or the only information about their disease is acquired from the death certificate, time consuming queries about patients must be performed by the CRRS's staff.

Calculation of patient survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the CRRS data base as alive. Since 2010, together with the upgrade of CRRS's database, an on-line connection with the Central Population Registry has been established using a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as the date of loss to follow-up. From 1985, since the uniform personal ID number has been used in Slovenia, the percentage of the lost to follow-up in CRRS is below 1%, furthermore, in patients registered in the last decade being only 0.1%.

When analysing the spatial distribution of cancer, the Decree on the standard classification of territorial units from the year 2000 that introduced the system of division of Slovenian territory at eleven administrative levels is followed. Our regular connection with the Registry of Spatial Units of the Surveying and Mapping Authority enables us to perform the exact mapping of patients' permanent address. Till the Annual Report 2002 the data have been presented by 9 health regions in Table 6 and in accordance with aforementioned decree 12 statistical regions are used to present the data since then.

Statistical regions of Slovenia



Preparation of data for computer processing

In CRRS specially trained nurses code the data retrieved from notifications of cancer in accordance with the international and internal CRRS guidelines.


Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); before, the 8th revision was used (ICD-8).

When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001. In this edition some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the third edition, chronic myeloproliferative disorders and myelodysplastic syndromes as well as polycythaemia are classified as malignant, the former two being assigned to C96.7 and the polycythaemia is classified under the topography code C94 from year 2001 on. From year 2012 on, the third edition with 2011 updates is used.

Development of molecular and genetic technologies enabled more detailed classification of the type of cellular changes, found in neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. All this correspond to greater number of disease types and its classification is constantly updating. In 2001, the World Health Organization published special classification of the lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and replaced several other classifications of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology (third revision, 2011 update) follows this classification. Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue are systemized in Table 10 according to 2008 version of the classification of the World Health Organization.

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961–1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered as well.

For stage description, a simplified definition of stages at diagnosis is used, classifying them into localized, regional and remote stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. In



solid tumors, the simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumor has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumor is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblastic tumors only T1 tumor is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumors classified as T3 and T4 (with aforementioned exceptions) and/or regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the remote stage (M1). Malignant lymphomas are classified according to Ann-Arbor System. Stage according to TNM or any other appropriate classification (e.g. FIGO for gynaecologic tumors) is also stored in the CRRS database, if available. In skin melanoma, Clark's level and Breslow's thickness are registered also.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in Table 3.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry that are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patients' records in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of patients in order to provide us with information about their vital status and among them we often find cases that have not been entered into the CRRS database yet.

In general, the registration is more complete where the registries have access to death certificates. This enables the registry to send out additional inquiries where disease for the deceased has not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well as in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and mortality are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. in the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by CRRS includes only the data on patients with permanent residence in Slovenia, regardless of the country where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2016 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also.

For assessing time trends, the average annual change was calculated with joinpoint regression analysis by Joinpoint Regression Program (Version 4.1.1 - August 2014), which follows the models developed by Kim et al.

Crude and age specific rates

Crude incidence rate is the number of new cases per 100,000 inhabitants, while crude mortality rate is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (= incidence or mortality), divided by the number of persons at risk of disease (or death) at the beginning of time interval; it is expressed per 100,000 person-years. The *age specific rate* expresses incidence or mortality rate in an individual five-year age group.

Age standardized rates

When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardization is needed to adjust the rate for the effect of age. The age-standardized rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In Table 2, besides crude cancer incidence rates, age standardized rates by direct method are presented, using World, European and Slovenian standard population. Age standardized mortality rates are also available at SLORA web-portal. In Table 6b the incidence rates in different statistical regions in Slovenia are compared using the Slovenian standard, which is the age structure of Slovenian 2002 census population. Because the standard population is always the same for both sexes, there are some situations where standardized rate is bigger than crude rate in one sex, usually in males who are on average younger, and smaller in the other.

Cumulative incidence rate and cumulative risk

The cumulative incidence (or mortality) rate (CR), (cumulative incidence rate is presented in the last column of Table 5) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 inhabitants. The cumulative rate can be interpreted as a form of direct age-standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4.

The cumulative risk is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed as a percentage. If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated from cumulative risk according to the following formula: $CRisk = 100 (1 - e^{-CR/100})$.

Cumulative incidence rate of breast cancer in females 7.6/100 can be used to estimate cumulative risk of breast cancer that is in this case 7.6%. This means that 7.6% of women born in 2013 (approximately one out of 13) are expected to develop breast cancer by their age of 74 in the absence of any other cause of death.

Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons living and ever diagnosed with cancer, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diseases.

Relative survival

Relative survival is an approximation of patients' survival in the case where the observed cancer would be considered as the only cause of death. Relative survival is a ratio between the observed and the expected survival, i.e. the survival expected with respect to gender and age in certain time period in the whole population the patients come from. The expected survival is calculated from general mortality data published routinely in the form of mortality tables for an individual country within the framework of its vital statistics. The relative survival for the needs of this report was calculated using the Slovenian annual complete yearly life tables using package *relsurv* in statistical software R.

It should be noted that the method used for survival calculation in this report is different from the one used to present survival at web-portal SLORA where the relative survival is computed by complete or Hakulinen's method. In this method the patients followed up for a shorter period of time are considered in the calculation only for the time when they were actually followed. Thus, a group diagnosed three years before the completion of study contributes to one- and three-year complete relative survival but not also to five-year survival.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In CRRS Annual Reports the population data on July 1 of a particular year are used, which are obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2013 by age and by sex are presented.

Age	Total	Males	Females
0–4	110,838	57,037	53,801
5–9	97,105	49,723	47,382
10–14	91,345	47,233	44,112
15–19	97,464	50,095	47,369
20–24	114,245	58,843	55,402
25–29	138,064	71,977	66,087
30–34	154,728	81,193	73,535
35–39	154,587	80,990	73,597
40–44	146,358	75,942	70,416
45–49	156,067	79,335	76,732
50–54	152,979	77,831	75,148
55–59	152,262	77,131	75,131
60–64	137,213	68,436	68,777
65–69	97,548	46,057	51,491
70–74	90,611	40,235	50,376
75–79	73,234	29,374	43,860
80+	94,466	28,226	66,240
Total	2,059,114	1,019,658	1,039,456

Population of Slovenia by age and by sex, July 1, 2013.

In the number of inhabitants by statistical regions (following table) the permanent, but not the temporary residence of the Slovenian citizens is used, contrary to the standard "statistical" definition.

Statistical region	Total	Males	Females
Pomurska	117,675	57,624	60,051
Podravska	322,748	159,897	162,851
Koroška	71,945	36,112	35,833
Savinjska	260,479	130,139	130,340
Zasavska	43,341	21,234	22,107
Spodnjeposavska	70,860	35,655	35,205
JV Slovenija	141,989	71,361	70,628
Osrednjeslovenska	542,447	265,100	277,347
Gorenjska	203,926	100,829	103,097
Notranjsko-Kraška	52,531	26,499	26,032
Goriška	119,019	59,390	59,629
Obalno-Kraška	112,154	55,818	56,336
Slovenia	2,059,114	1,019,658	1,039,456

Population by Slovenian statistical regions and by sex, July 1, 2013.

In 2013, 13,717 patients were diagnosed with cancer, 7,442 males and 6,275 females, and 6,071 patients died from cancer, 3,392 males and 2,679 females (*Figure 1*). From those born in 2013, one in two males and one in three females are expected to develop cancer by their age of 74 (*Table 5*).

At the end of December 2013, there were 94,073 people (41,607 males and 52,466 females) alive who were diagnosed with cancer at any time since the foundation of the CRRS (*Figure 1*). It is estimated that in 2016 there was about 14,800 Slovenian inhabitants newly diagnosed with cancer, approximately 8,300 males and 6,500 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.


The risk of cancer is slowly increasing and is the highest in older age groups; from all cancer patients, diagnosed in 2013, 61% males and 58% females were aged 65 or more at diagnosis. Cancer among children and young adults (till the age of 20) accounts for less than 1% (*Figure 2*). As Slovenian population is ageing, it is expected that the cancer burden will increase because of longer life expectancy.

As cancer incidence depends on the age structure of a population, *Table 2* presents crude as well as age standardized rates. For better comparison with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian, were applied.

First five most frequent cancers (skin – except melanoma, prostate, colorectal, lung and breast) comprise 59% of all new cancer cases (*Figure 3*). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2013 was prostate (20.0% of all new cases). In females, skin, non-melanoma was the most frequent cancer site with one fifth of all new cases (21.3%) (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased by 700% in males and by 470% in females. In the last 10 years, the average annual increase in males was 2.8% and 1.6% in females. The increase in crude mortality rate in the last 10 years was substantially lower; on average by 1.5% per year in males and by 1.7% in females (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of the population. In the last 10 years, the average annual increase in cumulative incidence rate in males was 0.9% and 0.6% in females. Cumulative mortality rate is decreasing in both sexes in the last 10 years, in males on average by 1.8% and in females on average by 1.0% annually. The decreasing mortality despite increasing incidence indicates improvement in treatment of cancer patients. It is a proof that more and more are cured of or living with and not dying from cancer.

The time trends of common cancers in males show that lung cancer incidence was increasing till the beginning of the nineties, while it became stable onwards (85/100.000) and is slowly decreasing (by 1.3% per year on average) and was finally overcome by prostate cancer (average increase by 6.3% per year) and by non-melanoma skin cancer (average increase by 5.7% per year). The huge increase in prostate cancer



incidence rate in the last years is not due to some new risk factor, but more frequent use of prostate specific antigen (PSA) test as an opportunistic screening method, resulting in detection of many cancers that would have never progressed or would even not have been detected during lifetime without screening. Similarly, the changes in the colorectal cancer incidence should be interpreted taking into consideration the changes in the diagnostic practice – in Slovenia the National colorectal cancer screening programme (SVIT) has been introduced in 2009. The average annual increase in colorectal cancers in males in the period 2004–2010 was 5.3%, but there was an average annual decrease of 10.5% in the following years 2011–2013. In females, the incidence rate of breast, lung and non-melanoma skin cancer is increasing, while the incidence of cervical cancer is rapidly decreasing since the introduction of the National cervical cancer screening programme (ZORA); the average annual decrease in last ten years was 5.0%. Like in males also in females the colorectal cancer incidence time trends has been changed because the national screening programme SVIT has been introduced: in the period 2004–2010 the incidence raised for 3.6% annually, but in the years 2011–2013 it decreased by 6.4% annually. The average annual percentage changes of incidence rates are presented in *Figure 5*.

In *Figure 6*, five-year relative survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites diagnosed in 2009–2013 is presented and compared to those diagnosed in 2004–2008. In males, the overall five-year relative survival increased for 6 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients with the most common male cancer the survival increased for 4 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. In females, the overall survival in both time periods was nearly the same, 59%.

In the current Annual Report a special attention is given to **rare cancers**. Their definition and burden in Slovenia is summarized in *Figures 7a–7e*. In the contrast to the common definition of rare disease (prevalence less than 50/100,000), the experts from the project Surveillance of Rare Cancers in Europe (RARECARE: www.rarecare.eu) defined the rare cancer as any cancer with crude incidence rate less than 6 per 100,000 inhabitants. Under this definition 198 rare cancers was identified by groups of experts. For better overview, rare cancers were grouped into 65 groups and further into 15 groups for some of the graphical presentations. All rare cancers combined account for more than 22% of all cancers in Slovenia in period 2004–2013; annually there are around 2,880 new rare cancers (142/100,000). In comparison to common cancers rare cancers occur more often in childhood and adolescence. As in any rare disease also in rare cancers the low incidence is the main obstacle to conduct clinical trials needed to develop effective treatments. One way to overcome this obstacle would be to precisely monitor the rare cancer burden on population level and establish centres of excellence for diagnostics and treatment.

In the majority of new cases, the diagnosis was confirmed microscopically. *Table 3* shows that in 2013, in 94.0% from 13,717 newly diagnosed cancer cases, the diagnosis was confirmed by histology or by cytology, in 5.7% with other investigations and

only 0.3% of cases were registered from death certificate only. This latter percentage has been similar for several years and represents the patients not treated in the hospital due to age or advanced disease. *Table 3* presents the number of new cases by cancer site by basis of diagnosis, while in *Table 4* their distribution by 5-year age group is presented. In *Table 5*, there are age specific incidence rates for all and specific cancer sites.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different age structure of population in these regions.

The morphology of tumours in 12,897 microscopically diagnosed cases is presented in *Table 7*. In this table, cases confirmed by histology (95%) and by cytology only (5%) are presented separately.

Table 8 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, which takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

Age distribution of extra nodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in *Table 9*. Owing to a small number of extra nodal sites, only the absolute numbers are given.

Table 10 shows the distribution of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues, published by World Health Organization.

Table 11 presents basic data on cancer patients' primary curative treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities is bigger than the number of new cases. *Table 11a* presents the mode of treatment of all cancer patients. *Tables 11b and 11c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at Institute of Oncology Ljubljana only (with few exceptions, irradiated abroad).

In *Table 12*, prevalence of all cancer patients and patients with selected cancer diseases on December 31, 2013 is presented. Along with lifetime prevalence, there is also partial prevalence (1-, 3-, 5- and 10-years).

In *Table 13*, there are official data on cancer mortality in 2013. The data for this table have been prepared at the National Institute of Public Health of the RS. Crude and age standardised mortality rates are available on the internet portal Slora (<http://www.slora.si/en/>).

Acknowledgement

Physicians, nurses, and the administrative staff from the Slovenian hospitals and other healthcare institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought and completed the missing information. If data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians.

At least half of data presented in the current report have been contributed by Mrs. Maruška Ferjančič and Mrs. Polona Škulj from the Ljubljana Institute of Oncology Hospital Registry.

The Report could not be published – at least with the currently assured high credibility of data – without the traditional good cooperation of the Republic of Slovenia Population Registry, National Institute of Public Health of RS, and Statistical Office of RS.

The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report.


Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. *Zdrav Vestn* 1951; 20: 264–77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961–1966.
- World health statistics report. Geneva: World Health Organization, 1970–1974.
- Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980.
- Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981–2004.
- Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160).
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds. Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC, 2013. URL: <http://ci5.iarc.fr>.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. URL: <http://globocan.iarc.fr>.
- Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: <http://eco.iarc.fr>.
- Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCORE-2 study. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCORE-3 study. *Ann Oncol* 2003; 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCORE-4 study. *Lancet Oncol* 2007; 8: 773–83.
- De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCORE-5 - a population-based study. *Lancet Oncol* 2013; published online Dec 5.
- Gatta G, Botta L, Rossi S et al. Childhood cancer survival in Europe 1999–2007: results of EUROCORE-5 - a population-based study. *Lancet Oncol* 2013; published online Dec 5.
- Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011; 47; 2493–511.
- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of cancer incidence in Slovenia 1978–1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer patients' survival in Slovenia 1963–1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
- Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997 (Cancer patients' survival in Slovenia 1983–1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.

- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009.
- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
- Savezni zavod za zdravstveno zaščito. Mednarodna klasifikacija bolezni, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstveno zaščito, 1970.
- Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseases and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. International statistical classification of diseases and related health problems. Tenth revision, edition 2010 (4th edition). Geneva: WHO Press, 2011.
- World Health Organisation. International classification of diseases for Oncology. 3rd Edition. Geneva: World Health Organisation, 2000.
- World Health Organisation. International Classification of Diseases for Oncology, Third Edition, First Revision. Geneva: World Health Organization, 2013.
- Swerdlow SH., Campo E, Harris NL et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO/IARC Classification of Tumours, 4th Edition, Volume 2. Geneva: World Health Organization, 2008.
- Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003; 15: 2751–66.
- SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2014. URL: <http://pxweb.stat.si/>.
- SI-STAT Data Portal. Ljubljana, Statistical Office of Republic of Slovenia, 2014. URL: <http://pxweb.stat.si/>.
- Dyba T, Hakulinen T, Päävärinta L. A simple non-linear model in incidence prediction. Statistics in Medicine 16: 2297–309, 1997.
- Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Statistics in medicine 2000; 19(3): 335–51.
- Pohar M, Stare J. Relative survival analysis in R. Computer Methods and Programs in Biomedicine 2006; 81: 272–8.
- Žagar T. Lifetables for Slovenia 1982–2007. Rostock: Max Planck, 2008. URL: <http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia>.


Slika 1: Breme raka, Slovenija 2013.

Figure 1: Cancer burden, Slovenia 2013.




Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2013.


Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2013.



Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2013.
Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2013.



MOŠKI IN ŽENSKE / MALES AND FEMALES



* Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)



Debelo črevo in danka / Colorectum (C18–C20)

Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33–C34)

Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64–C65)

Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2013.

Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2013.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2013.

Figure 5: Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2013.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level


Slika 6: Petletno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2004–2008 in 2009–2013 po spolu.

Figure 6: Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2004–2008 and 2009–2013 by sex.




Slika 6: Nadaljevanje.
Figure 6: Continued.

ŽENSKE / FEMALES



Slika 6: Nadaljevanje.
Figure 6: Continued.



Slika 7a: Tabela incidence in grobe incidenčne stopnje redkih, pogostih in nerazvrščenih rakov, Slovenija 2004–2013.

Figure 7a: Table of incidence and crude incidence rate of rare, common and unclassified cancers, Slovenia 2004–2013.

Primarna lokacija Primary site	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
Redki raki Rare cancers	28.768	141,7
Redki raki glave in vratu Head and neck rare cancers	4.505	22,2
Epitelijski tumorji nosne votline in sinusov Epithelial tumours of nasal cavity and sinuses	114	0,56
Epitelijski tumorji nazofarinksa Epithelial tumours of nasopharynx	98	0,48
Epitelijski tumorji velikih žlez slinavk in žlezam slinovkam podobni tumorji Epithelial tumours of major salivary glands and salivary-gland type tumours	276	1,36
Epitelijski tumorji hipofarinksa in grla Epithelial tumours of hypopharynx and larynx	1561	7,69
Epitelijski tumorji orofarinksa Epithelial tumours of oropharynx	1301	6,41
Epitelijski tumorji ustne votline in ustnice Epithelial tumours of oral cavity and lip	1133	5,58
Epitelijski tumorji očesa in očesnih adneksov Epithelial tumours of eye and adnexa	18	0,09
Epitelijski tumorji srednjega ušesa Epithelial tumours of middle ear	4	0,02
Redki raki prebavil Digestive rare cancers	4.021	19,8
Epitelijski tumorji požiralnika Epithelial tumours of oesophagus	754	3,71
Epitelijski tumorji želodca Epithelial tumours of stomach	363	1,79
Epitelijski tumorji tankega črevesa Epithelial tumours of small intestine	103	0,51
Epitelijski tumorji debelega črevesa Epithelial tumours of colon	26	0,13
Epitelijski tumorji rektuma Epithelial tumours of rectum	4	0,02
Epitelijski tumorji anusa in analnega kanala Epithelial tumours of anal canal	153	0,75
Epitelijski tumorji trebušne slinavke Epithelial tumours of pancreas	23	0,11
Epitelijski tumorji jeter in intrahepatičnih vodov Epithelial tumours of liver and intrahepatic bile tract (ibt)	972	4,79
Epitelijski tumorji žolčnika in drugih delov biliarnega trakta Epithelial tumours of gallbladder and extrahepatic biliary tract (ebt)	1623	7,99
Redki raki prsnih organov in mezoteliom Thoracic rare cancers and mesothelioma	1.565	7,7
Epitelijski tumor sapnika Epithelial tumour of trachea	48	0,24
Epitelijski tumor sapnice in pljuč Epithelial tumour of lung	1140	5,61
Epitelijski tumorji timusa Epithelial tumours of thymus	35	0,17
Mezoteliom Malignant mesothelioma	342	1,68
Redki raki dojke Breast rare cancers	701	3,5
Epitelijski tumorji dojke, ženske Epithelial tumours of breast, females	601	2,96
Epitelijski tumorji dojke, moški Epithelial tumours of breast, males	100	0,49

Slika 7a: Nadaljevanje.
Figure 7a: Continued.

Primarna lokacija Primary site	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
Redki raki ženskih spolnih organov Female genital rare cancers	3.817	18,8
Epitelijski tumorji materničnega telesa Epithelial tumours of corpus uteri	161	0,79
Epitelijski tumorji materničnega vratu Epithelial tumours of cervix uteri	1404	6,91
Epitelijski tumorji jajčnikov in jajcevodov Epithelial tumours of ovary and fallopian tube	1693	8,34
Neepitelijski tumorji jajčnika Non epithelial tumours of ovary	40	0,20
Epitelijski tumorji ženskega zunanega splovila in nožnice Epithelial tumours of vulva and vagina	517	2,55
Trofoblastni tumor posteljice Trophoblastic tumour of placenta	2	0,01
Redki raki moških spolnih organov Male genital rare cancers	1.152	5,7
Epitelijski tumorji prostate Epithelial tumours of prostate	47	0,23
Raki mod in in obmodnega tkiva Testicular and paratesticular cancers	993	4,89
Epitelijski tumorji penisa Epithelial tumours of penis	112	0,55
Redki raki sečil Urogenital rare cancers	517	2,5
Epitelijski tumorji ledvic Epithelial tumours of kidney	1	0,00
Epitelijski tumorji ledvičnega meha in sečevoda Epithelial tumours of pelvis and ureter	418	2,06
Epitelijski tumorji sečnice Epithelial tumours of urethra	20	0,10
Epitelijski tumorji sečnega mehurja Epithelial tumours of bladder	78	0,38
Redki kožni tumorji in melanom (brez kožnega) Rare skin tumors and non-cutaneous melanoma	328	1,6
Rak kožnih adneksov Adnexal carcinoma of skin	102	0,50
Melanom sluznice Malignant melanoma of mucosa and extracutaneous	71	0,35
Melanom žilnice Malignant melanoma of uvea	155	0,76
Redki embrionalni tumorji Rare embrionale tumours	110	0,53
Nevroblastom in ganglijonevroblastom Neuroblastoma and ganglioneuroblastoma	15	0,07
Nefroblastom Nephroblastoma	24	0,12
Retinoblastom Retinoblastoma	15	0,07
Hepatoblastom Hepatoblastoma	4	0,02
Plevropulmonalni blastom Pleuropulmonary blastoma	0	0,00
Blastom trebušne slinavke Pancreatoblastoma	0	0,00
Olfaktorni nevroblastom Olfactory neuroblastoma	8	0,04
Odontogeni maligni tumorji Odontogenic malignant tumors	0	0,00
Ekstragonadni germinalni tumorji Extragenadal germ cell tumours	44	0,22

Nadaljevanje —>
Continued —>


Slika 7a: Nadaljevanje.

Figure 7a: Continued.

Primarna lokacija Primary site	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
Redki sarkomi Rare sarcomas	1.340	6,6
Sarkomi mehkih tkiv Soft tissue sarcoma	881	4,34
Kostni sarkomi Bone sarcoma	165	0,81
Gastrointestinalni stromalni sarkomi Gastrointestinal stromal sarcoma	278	1,37
Kaposijevi sarkomi Kaposi's sarcoma	16	0,08
Nevroendokrini redki tumorji Neuroendocrine rare tumours	961	4,7
Nevroendokrini tumorji Neuroendocrine tumours	961	4,73
Redki tumorji endokrinih žlez Endocrine organs rare tumours	1.493	7,4
Karcinomi hipofize Carcinomas of pituitary gland	2	0,01
Karcinomi žleze ščitnice Carcinomas of thyroid gland	1441	7,10
Karcinomi obščitnice Carcinomas of parathyroid gland	4	0,02
Karcinomi skorje nadledvičnice Carcinoma of adrenal cortex	46	0,23
Redki tumorji centralnega živčnega sistema Central nervous system rare tumours	1.221	6,0
Tumorji centralnega živčnega sistema Tumours of central nervous system (cns)	1179	5,81
Embriionalni tumorji centralnega živčnega sistema Embryonal tumors of cns	42	0,21
Redki hematološki raki Haematological rare malignancies	6.680	32,9
Limfatične bolezni Lymphoid diseases	4224	20,80
Akutna mieloična levkemija in neoplazme prekursorjskih celic Acute myeloid leukemia and related precursor neoplasms	844	4,16
Mieloproliferativne neoplazme Myeloproliferative neoplasms	855	4,21
Mielodisplastični sindrom in mielodisplastična/mieloproliferativna bolezen Myelodysplastic syndrome and myelodysplastic/myeloproliferative diseases	748	3,68
Neoplazme histiocitov in dendritičnih celic Histiocytic and dendritic cell neoplasms	9	0,04
Drugi redki raki Other rare cancers	357	1,8
Drugi redki raki, nerazvrščeni Other rare cancers, unclassified	357	1,76
Pogosti raki Common cancers	92.799	457,0
Nerazvrščeni raki Unclassified sites	2.665	13,1
Ostale slabo opredeljene hematološke bolezni Other poorly defined hematological diseases	61	0,30
Druga slabo opredeljena mesta / neznani primarni malignom Other poorly defined sites / unknown primary sites	2031	10,00
Registrirani samo iz zdravniških poročil o vzroku smrti DCO cases (registered from death certificates only)	573	2,82


Slika 7b: Redki raki razporejeni v 15 skupin, Slovenija 2004–2013.

Figure 7b: Rare cancers categorized in 15 groups, Slovenia 2004–2013.




Slika 7c: Število skupin redkih rakov glede na grobo incidenčno stopnjo, Slovenija 2004–2013.

Figure 7c: Number groups of rare cancers by crude incidence rate, Slovenia 2004–2013.



Slika 7d: Odstotni delež redkih, pogostih in nerazvrščenih rakov po starostnih skupinah, Slovenija 2004–2013.
Figure 7d: Percentage distribution of rare, common and unclassified cancers by age group, Slovenia 2004–2013.



Slika 7e: Groba letna incidenčna stopnja redkih, pogostih in nerazvrščenih rakov, Slovenija 2004–2013.
Figure 7e: Crude annual incidence rates of rare, common and unclassified cancers by age group, Slovenia 2004–2013.




Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2004–2013 in 2016.

Table 1: Observed and estimated cancer incidence, Slovenia 2004–2013 and 2016.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Povprečne letne opazovane vrednosti 2004–2008		Povprečne letne opazovane vrednosti 2009–2013		Ocena za 2016			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
							Average annual observed values 2004–2008		Average annual observed values 2009–2013	
Number	Incidence rate per 100,000	Number	Incidence rate per 100,000	Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)				
C00–C96	Vse lokacije All sites	M+Ž	11609	577,5	13237	645,0	14785	14365–15205	716	696–737
		M	6090	616,7	7205	709,2	8259	7983–8535	807	780–834
		Ž	5519	539,6	6032	582,1	6527	6210–6843	627	597–657
C00–C14	Usta in žrelo Mouth and pharynx	M	264	26,7	273	26,9	272	229–314	27	22–31
		Ž	66	6,5	72	7,0	71	48–94	7	5–9
C15	Požiralnik Oesophagus	M	71	7,2	69	6,8	64	43–85	6	4–8
		Ž	15	1,5	16	1,5	16	4–27	1	0–3
C16	Želodec Stomach	M	292	29,6	295	29,1	285	241–329	28	24–32
		Ž	179	17,5	184	17,8	180	145–215	17	14–21
C18	Debelo črevo Colon	M	410	41,5	524	51,6	586	513–658	57	50–64
		Ž	344	33,7	395	38,1	414	359–469	40	35–45
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	351	35,6	416	40,9	440	383–497	43	37–49
		Ž	243	23,8	235	22,7	215	174–256	21	17–25
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	112	11,4	128	12,6	160	127–193	16	12–19
		Ž	44	4,3	46	4,5	48	28–68	5	3–7
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	60	6,1	69	6,8	80	55–104	8	5–10
		Ž	99	9,7	103	10,0	110	82–138	11	8–13
C25	Trebušna slinavka Pancreas	M	146	14,7	171	16,9	221	181–260	22	18–25
		Ž	160	15,7	175	16,9	186	149–223	18	14–21
C32	Grlo Larynx	M	95	9,6	92	9,0	84	60–107	8	6–11
		Ž	11	1,1	13	1,3	14	0–40	1	0–4
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	909	92,1	858	84,5	806	733–879	79	72–86
		Ž	315	30,8	391	37,7	458	403–513	44	39–49
C43	Maligni melanom kože Malignant melanoma of skin	M	185	18,7	246	24,3	325	217–433	32	21–42
		Ž	214	20,9	249	24,0	286	238–333	27	23–32
C44	Druge maligne neoplazme kože Skin, other malignomas	M	857	86,8	1141	112,3	1476	1376–1576	144	134–154
		Ž	943	92,2	1157	111,6	1378	1273–1484	132	122–143
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	28	2,9	29	2,8	28	14–43	3	1–4
		Ž	39	3,8	38	3,6	43	29–57	4	3–5
C50	Dojka Breast	M	7	0,7	13	1,3	20	7–33	2	1–3
		Ž	1142	111,7	1227	118,5	1307	1204–1409	126	116–135
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—
		Ž	165	16,2	131	12,7	102	77–126	10	7–12
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—
		Ž	292	28,6	313	30,2	320	267–372	31	26–36
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—
		Ž	182	17,8	161	15,6	152	48–255	15	5–25
C61	Prostata Prostate	M	1038	105,0	1458	143,5	1853	1741–1966	181	170–192
		Ž	—	—	—	—	—	—	—	—
C62	Modo Testis	M	98	9,9	101	9,9	102	75–128	10	7–13
		Ž	—	—	—	—	—	—	—	—
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	196	19,8	243	24,0	282	238–326	28	23–32
		Ž	113	11,0	120	11,6	137	49–225	13	5–22
C67	Sečni mehur Bladder	M	206	20,8	225	22,2	247	204–290	24	20–28
		Ž	73	7,1	82	7,9	93	62–123	9	6–12
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	78	7,9	81	8,0	81	57–106	8	6–10
		Ž	61	6,0	68	6,5	71	53–89	7	5–9
C73	Ščitnica Thyroid gland	M	31	3,1	40	4,0	52	31–72	5	3–7
		Ž	117	11,5	112	10,8	116	94–138	11	9–13
C81	Hodgkinova bolezen Hodgkin's disease	M	26	2,6	24	2,4	18	6–30	2	1–3
		Ž	19	1,8	25	2,5	22	11–33	2	1–3
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	123	12,4	169	16,6	208	107–309	20	10–30
		Ž	140	13,6	167	16,2	202	94–309	19	9–30
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	58	5,9	65	6,4	77	53–100	7	5–10
		Ž	56	5,5	65	6,3	74	46–103	7	4–10
C91–C95	Levkemije Leukaemias	M	136	13,8	153	15,0	170	143–197	17	14–19
		Ž	110	10,8	112	10,8	123	91–155	12	9–15

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2013.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2013.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR** – World standard	SSS* – evropski standard ASR** – European standard	SSS* – slovenski standard ASR** – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	13717	666,2	333,1	474,0	561,9
		M	7442	729,9	393,3	575,3	695,0
		Ž	6275	603,7	290,4	404,3	471,4
C00–C14	Usta in žrelo Mouth and pharynx	M	271	26,6	15,5	21,5	24,0
		Ž	69	6,6	3,3	4,6	5,2
C15	Požiralnik Oesophagus	M	64	6,3	3,4	5,0	5,7
		Ž	12	1,2	0,5	0,7	0,8
C16	Želodec Stomach	M	298	29,2	14,7	22,6	27,8
		Ž	178	17,1	6,8	10,2	12,4
C18	Debelo črevo Colon	M	436	42,8	22,1	33,3	41,2
		Ž	350	33,7	14,2	20,6	24,8
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	381	37,4	19,8	29,3	35,0
		Ž	208	20,0	8,0	12,0	14,4
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	139	13,6	7,1	10,6	13,0
		Ž	47	4,5	1,8	2,7	3,3
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	72	7,1	3,5	5,5	6,9
		Ž	104	10,0	3,4	5,3	6,6
C25	Trebušna slinavka Pancreas	M	183	17,9	8,8	13,7	16,9
		Ž	167	16,1	5,7	8,8	11,1
C32	Grlo Larynx	M	83	8,1	4,7	6,6	7,4
		Ž	18	1,7	0,9	1,2	1,4
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	869	85,2	45,8	66,9	79,3
		Ž	430	41,4	20,1	28,5	32,5
C43	Maligni melanom kože Malignant melanoma of skin	M	274	26,9	16,3	22,1	25,4
		Ž	250	24,1	14,8	19,0	21,3
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1350	132,4	67,2	102,7	127,8
		Ž	1336	128,5	52,7	77,4	93,9
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	33	3,2	1,8	2,6	3,0
		Ž	38	3,7	2,0	2,6	3,0
C50	Dojka Breast	M	13	1,3	0,6	1,0	1,2
		Ž	1252	120,4	66,6	90,2	102,2
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—
		Ž	124	11,9	8,0	10,0	10,9
C54	Maternično telo Corpus uteri	M	—	—	—	—	—
		Ž	311	29,9	14,3	20,6	23,7
C56	Jajčnik Ovary	M	—	—	—	—	—
		Ž	177	17,0	9,0	12,4	14,0
C61	Prostata Prostate	M	1485	145,6	76,0	113,0	139,6
		Ž	—	—	—	—	—
C62	Modo Testis	M	96	9,4	8,3	8,9	9,5
		Ž	—	—	—	—	—
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	266	26,1	14,4	20,8	24,7
		Ž	141	13,6	6,3	8,9	10,4
C67	Sečni mehur Bladder	M	254	24,9	11,8	18,9	24,1
		Ž	91	8,8	3,2	4,9	6,1
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	92	9,0	6,4	7,8	8,7
		Ž	74	7,1	4,5	5,4	6,0
C73	Ščitnica Thyroid gland	M	44	4,3	2,9	3,7	4,1
		Ž	116	11,2	8,5	10,0	10,9
C81	Hodgkinova bolezen Hodgkin's disease	M	23	2,3	2,0	2,1	2,3
		Ž	21	2,0	2,1	2,0	2,1
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	183	17,9	10,7	14,6	17,2
		Ž	191	18,4	8,5	12,0	14,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	63	6,2	3,1	4,8	5,9
		Ž	74	7,1	2,9	4,4	5,3
C91–C95	Levkemije Leukaemias	M	150	14,7	9,5	12,3	14,2
		Ž	110	10,6	5,7	7,3	8,3

* SSS – starostno standardizirana incidenčna stopnja na 100.000

**ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2013.

Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2013.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C00–C96	Vse lokacije All sites	M+Ž	13717	12897	94,0	783	5,7	37	0,3
		M	7442	6990	93,9	431	5,8	21	0,3
		Ž	6275	5907	94,1	352	5,6	16	0,3
C00	Ustnica Lip	M	13	13	—	0	—	0	—
		Ž	9	7	—	1	—	1	—
C01	Baza jezika Base of tongue	M	15	15	100	0	0	0	0
		Ž	3	3	—	0	—	0	—
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	23	23	100	0	0	0	0
		Ž	4	4	—	0	—	0	—
C03	Dlesen Gum	M	6	6	—	0	—	0	—
		Ž	6	6	—	0	—	0	—
C04	Ustno dno Floor of mouth	M	29	29	100	0	0	0	0
		Ž	6	6	—	0	—	0	—
C05	Nebo Palate	M	11	11	—	0	—	0	—
		Ž	7	7	—	0	—	0	—
C06	Usta, drugi deli Mouth, other & unspecified parts	M	14	14	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C07	Parotidna žleza Parotid gland	M	6	6	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	3	3	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C09	Tonzila Tonsil	M	40	40	100	0	0	0	0
		Ž	12	12	—	0	—	0	—
C10	Orofarinks Oropharynx	M	38	38	100	0	0	0	0
		Ž	5	4	—	1	—	0	—
C11	Nazofarinks Nasopharynx	M	13	13	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C12	Piriformni sinus Pyriform sinus	M	29	29	100	0	0	0	0
		Ž	3	3	—	0	—	0	—
C13	Hipofarinks Hypopharynx	M	30	27	90,0	3	10,0	0	0
		Ž	1	1	—	0	—	0	—
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	0	—	1	—	0	—
		Ž	0	0	—	0	—	0	—
C15	Požiralnik Oesophagus	M	64	59	92,2	5	7,8	0	0
		Ž	12	11	—	1	—	0	—
C16	Želodec Stomach	M	298	285	95,6	12	4,0	1	0,3
		Ž	178	175	98,3	3	1,7	0	0
C17	Tanko črevo Small intestine	M	16	16	100	0	0	0	0
		Ž	15	15	100	0	0	0	0
C18	Debelo črevo Colon	M	436	424	97,2	12	2,8	0	0
		Ž	350	323	92,3	27	7,7	0	0
C19	Rektosigmoidna zveza Rectosigmoid junction	M	71	68	95,8	3	4,2	0	0
		Ž	54	50	92,6	3	5,6	1	1,9
C20	Rektum Rectum	M	310	305	98,4	5	1,6	0	0
		Ž	154	150	97,4	3	1,9	1	0,6
C21	Anus in analni kanal Anus and anal canal	M	1	1	—	0	—	0	—
		Ž	6	6	—	0	—	0	—
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	139	62	44,6	77	55,4	0	0
		Ž	47	22	46,8	25	53,2	0	0
C23	Žolčnik Gallbladder	M	20	14	70,0	6	30,0	0	0
		Ž	52	37	71,2	15	28,8	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	52	34	65,4	18	34,6	0	0
		Ž	52	27	51,9	25	48,1	0	0

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C25	Trebušna slinavka Pancreas	M	183	108	59,0	75	41,0	0	0
		Ž	167	94	56,3	72	43,1	1	0,6
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	4	4	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	4	3	—	1	—	0	—
		Ž	4	4	—	0	—	0	—
C32	Grlo Larynx	M	83	82	98,8	1	1,2	0	0
		Ž	18	18	100	0	0	0	0
C33	Sapnik Trachea	M	0	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C34	Sapnica in pljuča Bronchus and lung	M	869	801	92,2	62	7,1	6	0,7
		Ž	429	387	90,2	38	8,9	4	0,9
C37	Timus Thymus	M	2	2	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	7	5	—	2	—	0	—
		Ž	2	1	—	1	—	0	—
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	4	4	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	6	6	—	0	—	0	—
		Ž	8	7	—	0	—	1	—
C43	Maligni melanom kože Malignant melanoma of skin	M	274	274	100	0	0	0	0
		Ž	250	250	100	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1350	1339	99,2	11	0,8	0	0
		Ž	1336	1328	99,4	8	0,6	0	0
C45	Mezoteliom Mesothelioma	M	30	30	100	0	0	0	0
		Ž	12	12	—	0	—	0	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	2	2	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	5	5	—	0	—	0	—
		Ž	20	20	100	0	0	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	28	28	100	0	0	0	0
		Ž	18	18	100	0	0	0	0
C50	Dojka Breast	M	13	13	—	0	—	0	—
		Ž	1252	1243	99,3	7	0,6	2	0,2
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—
		Ž	43	42	97,7	1	2,3	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—
		Ž	11	11	—	0	—	0	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—
		Ž	124	124	100	0	0	0	0
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—
		Ž	311	309	99,4	2	0,6	0	0
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—
		Ž	17	15	88,2	2	11,8	0	0
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—
		Ž	177	170	96,0	7	4,0	0	0

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—
		Ž	15	15	100	0	0	0	0
C58	Posteljica Placenta	M	—	—	—	—	—	—	—
		Ž	0	0	—	0	—	0	—
C60	Penis Penis	M	11	11	—	0	—	0	—
		Ž	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1485	1440	97,0	39	2,6	6	0,4
		Ž	—	—	—	—	—	—	—
C62	Modo Testis	M	96	96	100	0	0	0	0
		Ž	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	3	—	0	—	0	—
		Ž	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	242	219	90,5	23	9,5	0	0
		Ž	123	108	87,8	15	12,2	0	0
C65	Ledvični meh Renal pelvis	M	24	22	91,7	2	8,3	0	0
		Ž	18	18	100	0	0	0	0
C66	Sečevod Ureter	M	14	14	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C67	Sečni mehur Bladder	M	254	242	95,3	11	4,3	1	0,4
		Ž	91	85	93,4	6	6,6	0	0
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	2	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C69	Okoli očesni adneksi Eye and adnexa	M	10	9	—	1	—	0	—
		Ž	14	13	—	1	—	0	—
C70	Meninge Meninges	M	2	2	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C71	Možgani Brain	M	88	74	84,1	13	14,8	1	1,1
		Ž	73	54	74,0	19	26,0	0	0
C72	Hrbtani mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	2	2	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C73	Ščitnica Thyroid gland	M	44	44	100	0	0	0	0
		Ž	116	115	99,1	1	0,9	0	0
C74	Nadledvična žleza Adrenal gland	M	3	3	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	4	1	—	2	—	1	—
		Ž	26	9	34,6	16	61,5	1	3,8
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	18	18	100	0	0	0	0
		Ž	12	11	—	1	—	0	—
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	41	18	43,9	23	56,1	0	0
		Ž	50	23	46,0	26	52,0	1	2,0
C79	Metastaze, drugje Metastases of other sites	M	14	6	—	7	—	1	—
		Ž	15	5	33,3	10	66,7	0	0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	48	28	58,3	16	33,3	4	8,3
		Ž	60	42	70,0	15	25,0	3	5,0
C81	Hodgkinova bolezen Hodgkin's disease	M	23	23	100	0	0	0	0
		Ž	21	21	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	40	40	100	0	0	0	0
		Ž	65	65	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	109	109	100	0	0	0	0
		Ž	98	98	100	0	0	0	0

Nadaljevanje —>

Continued —>

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	20	20	100	0	0	0	0
		Ž	17	17	100	0	0	0	0
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	14	14	—	0	—	0	—
		Ž	11	11	—	0	—	0	—
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	2	2	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	63	63	100	0	0	0	0
		Ž	74	74	100	0	0	0	0
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	16	16	100	0	0	0	0
		Ž	4	4	—	0	—	0	—
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	61	61	100	0	0	0	0
		Ž	31	31	100	0	0	0	0
C92	Mieloična levkemija Myeloid leukaemia	M	60	60	100	0	0	0	0
		Ž	62	62	100	0	0	0	0
C93	Monocitna levkemija Monocytic leukaemia	M	2	2	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	8	8	—	0	—	0	—
		Ž	10	10	—	0	—	0	—
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	3	3	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	73	73	100	0	0	0	0
		Ž	57	57	100	0	0	0	0

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
D03	Melanom, in situ Melanoma, in situ	M	90	90	100	0	0	0	0
		Ž	83	83	100	0	0	0	0
D05	Dojka, in situ Breast, in situ	M	2	2	—	0	—	0	—
		Ž	104	104	100	0	0	0	0
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	—	—	—	—	—	—	—
		Ž	1048	1048	100	0	0	0	0
D09.0	Sečni mehur, in situ Bladder, in situ	M	143	143	100	0	0	0	0
		Ž	39	39	100	0	0	0	0
D32.0, D42.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	25	23	92,0	2	8,0	0	0
		Ž	71	64	90,1	7	9,9	0	0
D33.0–D33.2	Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M	1	0	—	1	—	0	—
		Ž	2	2	—	0	—	0	—
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	—	—	—	—	—	—	—
		Ž	56	56	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	3	1	—	2	—	0	—
		Ž	6	2	—	4	—	0	—

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2013.

Table 4: Cancer incidence by site, by sex and by age, Slovenia 2013.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00–C96	Vse lokacije All sites	M+Ž	13717	19	17	13	27	38	70	130	217	349	538	883	1359	1907	1742	1995	1905	2508
		M	7442	12	11	3	16	21	28	66	87	127	209	423	779	1139	1059	1242	1068	1152
		Ž	6275	7	6	10	11	17	42	64	130	222	329	460	580	768	683	753	837	1356
C00	Ustnica Lip	M	13	0	0	0	0	0	0	0	0	0	0	0	1	2	0	4	1	5
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	5
C01	Baza jezika Base of tongue	M	15	0	0	0	0	0	0	0	0	0	2	0	4	2	2	3	1	1
		Ž	3	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	23	0	0	0	0	0	0	0	0	2	2	2	6	5	3	2	0	1
		Ž	4	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	0
C03	Dlesen Gum	M	6	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	1	1
		Ž	6	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	3
C04	Ustno dno Floor of mouth	M	29	0	0	0	0	0	0	0	0	0	0	6	8	6	4	4	0	1
		Ž	6	0	0	0	0	0	0	0	0	0	0	2	2	1	0	1	0	0
C05	Nebo Palate	M	11	0	0	0	0	1	0	0	0	0	0	1	4	2	1	1	0	1
		Ž	7	0	0	0	0	1	0	0	0	0	0	2	1	1	0	1	0	1
C06	Usta, drugi deli Mouth, other & unspecified parts	M	14	0	0	0	0	0	0	0	0	0	3	0	7	2	0	2	0	0
		Ž	5	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	2
C07	Parotidna žleza Parotid gland	M	6	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	2	1
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	3	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	1	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
C09	Tonzila Tonsil	M	40	0	0	0	0	0	0	0	0	0	3	7	11	4	5	4	3	3
		Ž	12	0	0	0	0	0	0	0	0	1	0	2	2	5	0	2	0	0
C10	Orofarinks Oropharynx	M	38	0	0	0	0	0	0	0	0	0	4	3	9	9	7	5	0	1
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	1
C11	Nazofarinks Nasopharynx	M	13	0	0	0	0	0	0	0	1	1	0	2	2	1	2	2	2	0
		Ž	3	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0
C12	Piriformni sinus Pyriform sinus	M	29	0	0	0	0	0	1	1	0	0	3	4	5	7	5	2	1	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0
C13	Hipofarinks Hypopharynx	M	30	0	0	0	0	0	0	0	0	0	2	4	6	9	5	2	1	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	64	0	0	0	0	0	0	0	0	1	3	8	12	11	6	10	3	10
		Ž	12	0	0	0	0	0	0	0	0	0	1	0	1	2	1	2	1	4
C16	Želodec Stomach	M	298	0	0	0	0	0	0	0	5	5	10	15	38	34	29	52	55	55
		Ž	178	0	0	0	0	0	0	1	1	3	7	14	12	11	18	25	32	54
C17	Tanko črevo Small intestine	M	16	0	0	0	0	0	0	0	0	0	1	0	2	5	1	3	3	1
		Ž	15	0	0	0	0	0	0	0	0	0	1	2	0	3	0	2	3	4
C18	Debelo črevo Colon	M	436	0	1	0	1	0	1	1	5	4	9	24	29	67	65	70	78	81
		Ž	350	0	0	1	0	1	0	0	5	9	14	17	24	39	40	45	55	100
C19	Rektosigmoidna zveza Rectosigmoid junction	M	71	0	0	0	0	0	0	0	0	1	5	6	10	9	7	12	6	15
		Ž	54	0	0	0	0	0	0	0	1	0	2	2	4	6	4	7	9	19
C20	Rektum Rectum	M	310	0	0	0	0	1	0	2	0	2	14	26	39	56	35	47	43	45
		Ž	154	0	0	0	0	0	0	0	1	4	4	9	15	17	17	19	26	42
C21	Anus in analni kanal Anus and anal canal	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
		Ž	6	0	0	0	0	0	1	0	0	0	0	0	1	1	1	2	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	139	0	0	0	0	0	0	0	0	0	1	5	14	27	29	25	22	16
		Ž	47	0	0	0	0	0	0	0	0	1	0	4	1	7	6	4	14	10
C23	Žolčnik Gallbladder	M	20	0	0	0	0	0	0	0	0	0	1	1	0	1	2	9	1	5
		Ž	52	0	0	0	0	0	0	0	0	0	2	1	4	6	6	5	8	20
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	52	0	0	0	0	0	0	0	0	1	0	5	5	4	5	11	10	11
		Ž	52	0	0	0	0	0	0	0	0	1	0	0	2	4	7	6	8	24
C25	Trebušna slinavka Pancreas	M	183	0	0	0	0	0	0	1	1	1	1	9	22	26	19	30	30	43
		Ž	167	0	0	0	0	0	0	1	0	2	0	5	7	17	16	33	31	55
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>

Continued —>

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	4	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C31	Obnosni sinusi Accessory sinuses	M	4	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	1
		Ž	4	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	0
C32	Grlo Larynx	M	83	0	0	0	0	0	0	0	0	1	6	16	17	15	9	6	8	5
		Ž	18	0	0	0	0	0	0	0	0	1	0	1	4	4	1	4	1	2
C33	Sapnik Trachea	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C34	Sapnica in pljuča Bronchus and lung	M	869	0	0	0	0	0	0	0	1	6	21	54	117	185	156	113	112	104
		Ž	429	0	0	0	0	0	0	1	2	8	15	33	65	79	61	51	49	65
C37	Timus Thymus	M	2	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	7	0	0	0	1	0	0	0	0	1	0	0	4	0	0	0	1	0
		Ž	2	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	4	0	0	1	0	0	1	0	1	0	0	1	0	0	0	0	0	0
		Ž	3	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	6	0	0	0	0	0	0	0	0	3	0	0	0	2	0	0	1	0
		Ž	8	0	1	1	1	0	1	0	0	0	1	0	0	2	0	0	0	1
C43	Maligni melanom kože Malignant melanoma of skin	M	274	0	0	0	4	1	2	11	15	13	21	27	31	38	24	34	20	33
		Ž	250	0	0	1	2	0	7	10	16	20	26	16	26	29	28	25	17	27
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1350	0	0	0	0	2	5	12	21	22	35	60	100	156	171	238	223	305
		Ž	1336	0	0	0	0	1	3	8	20	33	63	67	87	121	137	177	224	395
C45	Mezoteliom Mesothelioma	M	30	0	0	0	0	0	0	0	0	1	3	0	2	2	6	6	7	3
		Ž	12	0	0	0	0	0	0	0	0	0	2	1	1	0	3	1	3	1
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	2	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	5	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1
		Ž	20	0	0	0	0	0	0	0	0	0	0	1	3	7	4	2	2	1
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	28	0	0	0	0	0	1	0	0	1	4	4	5	3	0	5	2	3
		Ž	18	0	0	0	0	0	2	0	0	1	1	2	0	3	1	3	1	4
C50	Dojka Breast	M	13	0	0	0	0	0	0	1	0	0	0	0	1	3	1	2	2	3
		Ž	1252	0	0	0	0	0	6	22	32	82	111	128	146	183	155	126	119	142
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	43	0	0	0	0	0	0	0	1	1	2	1	2	1	4	6	3	22
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	11	0	0	0	0	0	0	0	0	0	0	2	1	1	0	0	2	5
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	124	0	0	0	0	2	6	5	7	10	11	16	11	27	11	5	6	7
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	311	0	0	0	0	0	0	0	1	4	16	30	47	42	42	41	42	46
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	17	0	0	0	0	0	0	0	1	0	0	4	0	2	2	1	2	5
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	177	0	0	0	0	1	1	0	2	4	15	26	25	25	17	21	16	24
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	15	0	0	0	0	0	0	0	0	0	0	2	2	3	1	0	4	3
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis Penis	M	11	0	0	0	0	0	0	1	1	0	2	1	1	2	1	0	1	1
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1485	0	0	0	0	0	0	0	0	2	11	37	149	270	286	344	233	153
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C62	Modo Testis	M	96	1	0	0	2	9	9	24	19	19	4	6	2	1	0	0	0	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	242	1	0	0	0	0	0	0	0	11	11	21	29	40	31	47	22	29
		Ž	123	1	1	0	0	0	1	1	1	1	3	11	13	11	19	18	14	28
C65	Ledvični meh Renal pelvis	M	24	0	0	0	0	0	0	0	0	0	0	2	3	2	6	1	4	6
		Ž	18	0	0	0	0	0	0	0	0	0	1	1	1	2	1	3	5	4
C66	Sečevod Ureter	M	14	0	0	0	0	0	0	0	0	0	0	0	0	2	1	3	2	3
		Ž	5	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	3	0
C67	Sečni mehur Bladder	M	254	0	0	0	0	0	0	1	0	1	3	6	16	28	33	42	50	74
		Ž	91	0	0	0	0	0	0	0	0	1	0	3	3	10	12	16	17	29
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	1
C69	Oko in očesni adneksi Eye and adnexa	M	10	1	0	0	0	0	0	0	0	0	0	0	1	2	2	0	3	1
		Ž	14	1	1	0	0	0	0	0	0	0	1	1	3	1	2	1	1	2
C70	Meninge Meninges	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
		Ž	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
C71	Možgani Brain	M	88	2	2	0	2	1	1	2	3	7	7	10	5	14	6	8	11	7
		Ž	73	2	1	1	1	0	1	1	5	5	3	3	6	9	5	9	10	11
C72	Hrbtni mozeg, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	2	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	M	44	0	0	0	0	2	1	2	1	6	3	6	6	4	5	5	0	3
		Ž	116	0	0	0	3	3	8	8	17	11	10	12	10	15	4	3	6	6
C74	Nadledvična žleza Adrenal gland	M	3	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1
		Ž	3	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2
		Ž	26	0	0	0	0	0	0	0	0	1	0	0	1	3	1	4	3	13
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	18	0	0	0	0	0	0	0	1	1	1	3	1	5	3	2	1	0
		Ž	12	0	0	0	0	0	0	0	0	0	1	2	0	0	1	2	1	5
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	41	0	0	0	0	0	0	0	0	0	0	1	1	2	4	4	9	20
		Ž	50	0	0	0	0	0	1	1	0	1	0	1	0	3	3	2	10	28
C79	Metastaze, drugje Metastases of other sites	M	14	0	0	0	0	0	0	0	0	0	1	0	2	2	0	2	3	4
		Ž	15	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	2	7
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	48	0	0	0	0	0	0	0	1	0	0	2	8	7	5	6	8	11
		Ž	60	0	0	0	0	0	0	1	0	3	1	2	3	3	3	11	10	23
C81	Hodgkinova bolezen Hodgkin's disease	M	23	0	0	0	3	2	2	2	2	3	0	1	2	2	0	0	1	3
		Ž	21	0	0	2	3	2	2	1	3	0	0	1	1	0	0	2	2	2
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	40	0	0	0	0	0	0	0	0	1	1	4	3	12	6	7	3	3
		Ž	65	0	0	0	0	0	1	0	6	0	2	9	11	15	4	4	6	7
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	109	1	4	0	1	0	0	2	2	3	4	11	12	10	13	14	20	12
		Ž	98	0	0	0	0	0	1	2	4	2	1	8	8	5	6	15	21	25
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	20	0	0	1	0	0	0	0	1	0	1	3	0	2	1	4	4	3
		Ž	17	0	1	0	0	0	0	0	1	3	2	0	1	0	0	1	3	5
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	14	0	0	0	0	0	0	0	1	0	0	0	3	2	2	1	5	0
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	8

Nadaljevanje —>

Continued —>

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M Ž	2 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	1 0	
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M Ž	63 74	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 2	1 1	3 5	6 7	8 7	9 8	13 12	7 17	15 15	
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M Ž	16 4	4 0	3 1	1 0	2 0	0 0	1 0	0 0	1 0	1 0	0 0	0 1	0 0	2 0	1 0	0 1	0 0	0 1	
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M Ž	61 31	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	0 0	0 1	1 1	8 4	8 2	12 5	11 1	9 7	11 9	
C92	Mieločna levkemija Myeloid leukaemia	M Ž	60 62	1 2	0 1	0 0	0 3	0 0	1 2	0 0	1 1	0 1	2 3	3 3	5 5	4 7	8 6	12 11	9 5	10 14	
C93	Monocitna levkemija Monocytic leukaemia	M Ž	2 2	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 1	
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M Ž	8 10	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	1 0	1 2	2 1	1 3	0 0	0 2	1 0	1 2	
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M Ž	3 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0	1 1	0 0	1 0	
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M Ž	73 57	0 0	0 0	0 0	0 1	1 0	0 0	0 0	0 0	0 3	3 0	5 3	4 2	5 8	14 12	10 6	15 7	16 15	

Zgoraj neupoštevani

Not included above

Not included above				Starost Age																	
Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
D03	Melanom, in situ	M	90	0	0	0	0	0	3	2	8	7	6	6	7	11	6	11	9	14	
	Melanoma, in situ	Ž	83	0	0	0	0	1	2	4	3	5	10	5	12	9	11	10	5	6	
D05	Dojka, in situ	M	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	
	Breast, in situ	Ž	104	0	0	0	0	0	0	0	5	2	14	19	13	20	16	9	3	3	
D06	Maternični vrat, CIN III	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
	Cervix uteri, in situ	Ž	1048	0	0	0	3	101	199	216	173	130	79	53	33	32	16	4	7	2	
D09.0	Sečni mehur, in situ	M	143	0	0	0	0	0	0	2	2	2	5	10	14	20	26	26	16	20	
	Bladder, in situ	Ž	39	0	0	0	0	0	0	0	0	1	1	2	3	8	8	4	3	9	
D32.0, D42.0	Meninge, benigna neoplazma	M	25	0	0	0	0	0	0	0	0	2	3	7	1	2	2	3	2	3	
	Benign neoplasm of meninges	Ž	71	0	0	0	0	0	0	2	5	4	8	4	2	11	8	8	6	13	
D33.0–D33.2	Meninge, benigna neoplazma in neoplazma negotovega značaja	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
	Benign neoplasm and neoplasm of uncertain behaviour of meninges	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	
D39.1	Jajčnik, neoplazma negotovega značaja	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
	Ovary, neoplasm of uncertain behavior	Ž	56	0	0	0	0	3	2	3	4	2	5	6	10	7	4	7	2	1	
D43.0–D43.2	Možgani, neopredeljeno	M	3	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	
	CNS, uncertain or unknown	Ž	6	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	2	

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2013.

Table 5: Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2013.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C00–C96	Vse lokacije All sites	M+Ž	666,2	17,1	17,5	14,2	27,7	33,3	50,7	84,0	140,4	238,5	344,7	577,2	892,5	1389,8	1785,8	2201,7	2601,3	2654,9	39,1
		M	729,9	21,0	22,1	6,4	31,9	35,7	38,9	81,3	107,4	167,2	263,4	543,5	1010,0	1664,3	2299,3	3086,9	3635,9	4081,3	46,9
		Ž	603,7	13,0	12,7	22,7	23,2	30,7	63,6	87,0	176,6	315,3	428,8	612,1	772,0	1116,7	1326,4	1494,8	1908,3	2047,1	32,5
C00	Ustnica Lip	M	1,3	0	0	0	0	0	0	0	0	0	0	0	1,3	2,9	0	9,9	3,4	17,7	0,1
		Ž	0,9	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	4,0	2,3	7,5	<0,1
C01	Baza jezika Base of tongue	M	1,5	0	0	0	0	0	0	0	0	0	2,5	0	5,2	2,9	4,3	7,5	3,4	3,5	0,1
		Ž	0,3	0	0	0	0	0	0	0	0	1,4	0	0	2,7	0	0	0	0	0	<0,1
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	2,3	0	0	0	0	0	0	0	0	2,6	2,5	2,6	7,8	7,3	6,5	5,0	0	3,5	0,2
		Ž	0,4	0	0	0	0	0	0	0	0	0	1,3	0	0	1,5	0	2,0	2,3	0	<0,1
C03	Dlesen Gum	M	0,6	0	0	0	0	0	0	0	0	0	0	1,3	1,3	1,5	2,2	0	3,4	3,5	<0,1
		Ž	0,6	0	0	0	0	0	0	0	0	0	0	1,3	0	1,5	0	2,0	0	4,5	<0,1
C04	Ustno dno Floor of mouth	M	2,8	0	0	0	0	0	0	0	0	0	0	7,7	10,4	8,8	8,7	9,9	0	3,5	0,2
		Ž	0,6	0	0	0	0	0	0	0	0	0	0	0	2,7	2,9	1,9	0	2,3	0	<0,1
C05	Nebo Palate	M	1,1	0	0	0	0	1,7	0	0	0	0	0	1,3	5,2	2,9	2,2	2,5	0	3,5	0,1
		Ž	0,7	0	0	0	0	1,8	0	0	0	0	0	2,7	1,3	1,5	0	2,0	0	1,5	<0,1
C06	Usta, drugi deli Mouth, other & unspecified parts	M	1,4	0	0	0	0	0	0	0	0	0	0	3,9	0	10,2	4,3	0	6,8	0	0,1
		Ž	0,5	0	0	0	0	0	0	0	0	1,4	0	0	0	2,9	0	0	0	3,0	<0,1
C07	Parotidna žleza Parotid gland	M	0,6	0	0	0	0	0	0	0	0	2,6	0	0	0	1,5	0	0	6,8	3,5	<0,1
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	1,5	1,9	0	0	1,5	<0,1
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0,3	0	0	0	0	0	0	0	2,5	0	0	0	0	0	0	0	3,4	0	<0,1
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,6	0	0,0
C09	Tonzila Tonsil	M	3,9	0	0	0	0	0	0	0	0	0	3,8	9,0	14,3	5,8	10,9	9,9	10,2	10,6	0,3
		Ž	1,2	0	0	0	0	0	0	0	0	1,4	0	2,7	2,7	7,3	0	4,0	0	0	0,1
C10	Orofarinks Oropharynx	M	3,7	0	0	0	0	0	0	0	0	0	5,0	3,9	11,7	13,2	15,2	12,4	0	3,5	0,3
		Ž	0,5	0	0	0	0	0	0	0	0	0	0	0	0	1,5	1,9	4,0	0	1,5	<0,1
C11	Nazofarinks Nasopharynx	M	1,3	0	0	0	0	0	0	0	1,2	1,3	0	2,6	2,6	1,5	4,3	5,0	6,8	0	0,1
		Ž	0,3	0	0	0	0	0	0	0	0	1,4	0	0	0	1,5	0	0	2,3	0	<0,1
C12	Piriformni sinus Pyriform sinus	M	2,8	0	0	0	0	0	1,4	1,2	0	0	3,8	5,1	6,5	10,2	10,9	5,0	3,4	0	0,2
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	1,3	1,5	0	2,0	0	0	<0,1
C13	Hipofarinks Hypopharynx	M	2,9	0	0	0	0	0	0	0	0	0	2,5	5,1	7,8	13,2	10,9	5,0	3,4	3,5	0,2
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	<0,1
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,4	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C15	Požiralnik Oesophagus	M	6,3	0	0	0	0	0	0	0	0	1,3	3,8	10,3	15,6	16,1	13,0	24,9	10,2	35,4	0,4
		Ž	1,2	0	0	0	0	0	0	0	0	0	1,3	0	1,3	2,9	1,9	4,0	2,3	6,0	0,1
C16	Želodec Stomach	M	29,2	0	0	0	0	0	0	0	6,2	6,6	12,6	19,3	49,3	49,7	63,0	129,2	187,2	194,9	1,7
		Ž	17,1	0	0	0	0	0	0	1,4	1,4	4,3	9,1	18,6	16,0	16,0	35,0	49,6	73,0	81,5	0,8
C17	Tanko črevo Small intestine	M	1,6	0	0	0	0	0	0	0	0	0	1,3	0	2,6	7,3	2,2	7,5	10,2	3,5	0,1
		Ž	1,4	0	0	0	0	0	0	0	0	0	1,3	2,7	0	4,4	0	4,0	6,8	6,0	0,1
C18	Debelo črevo Colon	M	42,8	0	2,0	0	2,0	0	1,4	1,2	6,2	5,3	11,3	30,8	37,6	97,9	141,1	174,0	265,5	287,0	2,6
		Ž	33,7	0	0	2,3	0	1,8	0	0	6,8	12,8	18,2	22,6	31,9	56,7	77,7	89,3	125,4	151,0	1,6

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	7,0	0	0	0	0	0	0	0	0	1,3	6,3	7,7	13,0	13,2	15,2	29,8	20,4	53,1	0,4	
		Ž	5,2	0	0	0	0	0	0	0	1,4	0	2,6	2,7	5,3	8,7	7,8	13,9	20,5	28,7	0,2	
C20	Rektum Rectum	M	30,4	0	0	0	0	1,7	0	2,5	0	2,6	17,6	33,4	50,6	81,8	76,0	116,8	146,4	159,4	1,9	
		Ž	14,8	0	0	0	0	0	0	0	1,4	5,7	5,2	12,0	20,0	24,7	33,0	37,7	59,3	63,4	0,7	
C21	Anus in analni kanal Anus and anal canal	M	0,1	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	< 0,1	
		Ž	0,6	0	0	0	0	0	1,5	0	0	0	0	0	1,3	1,5	1,9	4,0	0	0	0,1	
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	13,6	0	0	0	0	0	0	0	0	0	1,3	6,4	18,2	39,5	63,0	62,1	74,9	56,7	1,0	
		Ž	4,5	0	0	0	0	0	0	0	0	1,4	0	5,3	1,3	10,2	11,7	7,9	31,9	15,1	0,2	
C23	Žolčnik Gallbladder	M	2,0	0	0	0	0	0	0	0	0	0	1,3	1,3	0	1,5	4,3	22,4	3,4	17,7	0,2	
		Ž	5,0	0	0	0	0	0	0	0	0	0	2,6	1,3	5,3	8,7	11,7	9,9	18,2	30,2	0,2	
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	5,1	0	0	0	0	0	0	0	0	1,3	0	6,4	6,5	5,8	10,9	27,3	34,0	39,0	0,3	
		Ž	5,0	0	0	0	0	0	0	0	0	1,4	0	0	2,7	5,8	13,6	11,9	18,2	36,2	0,2	
C25	Trebušna slinavka Pancreas	M	17,9	0	0	0	0	0	0	1,2	1,2	1,3	1,3	11,6	28,5	38,0	41,3	74,6	102,1	152,3	1,0	
		Ž	16,1	0	0	0	0	0	0	1,4	0	2,8	0	6,7	9,3	24,7	31,1	65,5	70,7	83,0	0,7	
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0,4	0	0	0	0	0	0	1,2	0	0	0	0	1,3	0	2,2	0	0	3,5	< 0,1	
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C31	Obnosni sinusi Accessory sinuses	M	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	2,5	3,4	3,5	< 0,1	
		Ž	0,4	0	0	0	0	0	0	0	0	0	1,3	0	0	1,5	1,9	2,0	0	0	< 0,1	
C32	Grlo Larynx	M	8,1	0	0	0	0	0	0	0	0	1,3	7,6	20,6	22,0	21,9	19,5	14,9	27,2	17,7	0,5	
		Ž	1,7	0	0	0	0	0	0	0	0	1,4	0	1,3	5,3	5,8	1,9	7,9	2,3	3,0	0,1	
C33	Sapnik Trachea	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	< 0,1	
C34	Sapnica in pljuča Bronchus and lung	M	85,2	0	0	0	0	0	0	0	1,2	7,9	26,5	69,4	151,7	270,3	338,7	280,9	381,3	368,5	5,7	
		Ž	41,3	0	0	0	0	0	0	1,4	2,7	11,4	19,5	43,9	86,5	114,9	118,5	101,2	111,7	98,1	2,5	
C37	Timus Thymus	M	0,2	0	0	0	0	0	1,4	0	0	0	0	0	0	1,5	0	0	0	0	< 0,1	
		Ž	0,2	0	0	0	0	0	0	0	0	0	1,3	0	1,3	0	0	0	0	0	< 0,1	
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	0,7	0	0	0	2,0	0	0	0	0	1,3	0	0	5,2	0	0	0	3,4	0	< 0,1	
		Ž	0,2	0	0	0	0	1,8	0	0	0	0	0	0	0	0	1,9	0	0	0	< 0,1	
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	0,4	0	0	2,1	0	0	1,4	0	1,2	0	0	1,3	0	0	0	0	0	0	< 0,1	
		Ž	0,3	0	0	2,3	2,1	1,8	0	0	0	0	0	0	0	0	0	0	0	0	< 0,1	

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	0,6	0	0	0	0	0	0	0	0	4,0	0	0	0	2,9	0	0	3,4	0	< 0,1	
		Ž	0,8	0	2,1	2,3	2,1	0	1,5	0	0	0	1,3	0	0	2,9	0	0	0	1,5	0,1	
C43	Malignni melanom kože Malignant melanoma of skin	M	26,9	0	0	0	8,0	1,7	2,8	13,5	18,5	17,1	26,5	34,7	40,2	55,5	52,1	84,5	68,1	116,9	1,8	
		Ž	24,1	0	0	2,3	4,2	0	10,6	13,6	21,7	28,4	33,9	21,3	34,6	42,2	54,4	49,6	38,8	40,8	1,6	
C44	Druge maligne neoplazme kože Skin, other malignomas	M	132,4	0	0	0	0	3,4	6,9	14,8	25,9	29,0	44,1	77,1	129,6	228,0	371,3	591,5	759,2	1080,6	7,6	
		Ž	128,5	0	0	0	0	1,8	4,5	10,9	27,2	46,9	82,1	89,2	115,8	175,9	266,1	351,4	510,7	596,3	5,9	
C45	Mezoteliom Mesothelioma	M	2,9	0	0	0	0	0	0	0	0	1,3	3,8	0	2,6	2,9	13,0	14,9	23,8	10,6	0,2	
		Ž	1,2	0	0	0	0	0	0	0	0	0	2,6	1,3	1,3	0	5,8	2,0	6,8	1,5	0,1	
C46	Kaposijev sarkom Kaposi's sarcoma	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,5	0,0	
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0,2	1,8	0	0	0	0	1,4	0	0	0	0	0	0	0	0	0	0	0	< 0,1	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	0	< 0,1	
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	0,5	0	0	0	0	0	0	0	0	0	0	0	1,3	0	2,2	2,5	3,4	3,5	< 0,1	
		Ž	1,9	0	0	0	0	0	0	0	0	0	0	1,3	4,0	10,2	7,8	4,0	4,6	1,5	0,1	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	2,7	0	0	0	0	0	1,4	0	0	1,3	5,0	5,1	6,5	4,4	0	12,4	6,8	10,6	0,2	
		Ž	1,7	0	0	0	0	0	3,0	0	0	1,4	1,3	2,7	0	4,4	1,9	6,0	2,3	6,0	0,1	
C50	Dojka Breast	M	1,3	0	0	0	0	0	0	1,2	0	0	0	0	1,3	4,4	2,2	5,0	6,8	10,6	0,1	
		Ž	120,4	0	0	0	0	0	9,1	29,9	43,5	116,5	144,7	170,3	194,3	266,1	301,0	250,1	271,3	214,4	7,6	
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	4,1	0	0	0	0	0	0	0	1,4	1,4	2,6	1,3	2,7	1,5	7,8	11,9	6,8	33,2	0,2	
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	1,1	0	0	0	0	0	0	0	0	0	0	2,7	1,3	1,5	0	0	4,6	7,5	< 0,1	
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	11,9	0	0	0	0	3,6	9,1	6,8	9,5	14,2	14,3	21,3	14,6	39,3	21,4	9,9	13,7	10,6	0,8	
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	29,9	0	0	0	0	0	0	0	1,4	5,7	20,9	39,9	62,6	61,1	81,6	81,4	95,8	69,4	1,8	
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	1,6	0	0	0	0	0	0	0	1,4	0	0	5,3	0	2,9	3,9	2,0	4,6	7,5	0,1	
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	17,0	0	0	0	0	1,8	1,5	0	2,7	5,7	19,5	34,6	33,3	36,3	33,0	41,7	36,5	36,2	1,1	
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	1,4	0	0	0	0	0	0	0	0	0	0	2,7	2,7	4,4	1,9	0	9,1	4,5	0,1	
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C60	Penis Penis	M	1,1	0	0	0	0	0	0	1,2	1,2	0	2,5	1,3	1,3	2,9	2,2	0	3,4	3,5	0,1	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C61	Prostata Prostate	M	145,6	0	0	0	0	0	0	0	0	2,6	13,9	47,5	193,2	394,5	621,0	855,0	793,2	542,1	10,6	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
C62	Modo Testis	M	9,4	1,8	0	0	4,0	15,3	12,5	29,6	23,5	25,0	5,0	7,7	2,6	1,5	0	0	0	0	0,6	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0,3	0	0	0	0	0	0	0	0	0	0	1,3	0	0	2,2	0	3,4	0	< 0,1	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
C64	Ledvica razen meha Kidney, except renal pelvis	M	23,7	1,8	0	0	0	0	0	0	0	14,5	13,9	27,0	37,6	58,4	67,3	116,8	74,9	102,7	1,7	
		Ž	11,8	1,9	2,1	0	0	0	1,5	1,4	1,4	1,4	3,9	14,6	17,3	16,0	36,9	35,7	31,9	42,3	0,7	
C65	Ledvični meh Renal pelvis	M	2,4	0	0	0	0	0	0	0	0	0	0	2,6	3,9	2,9	13,0	2,5	13,6	21,3	0,1	
		Ž	1,7	0	0	0	0	0	0	0	0	0	1,3	1,3	1,3	2,9	1,9	6,0	11,4	6,0	0,1	
C66	Sečevod Ureter	M	1,4	0	0	0	0	0	0	0	0	0	0	0	2,6	1,5	6,5	7,5	6,8	10,6	0,1	
		Ž	0,5	0	0	0	0	0	0	0	0	0	1,3	0	0	1,5	0	0	6,8	0	< 0,1	
C67	Sečni mehur Bladder	M	24,9	0	0	0	0	0	0	1,2	0	1,3	3,8	7,7	20,7	40,9	71,7	104,4	170,2	262,2	1,3	
		Ž	8,8	0	0	0	0	0	0	0	0	1,4	0	4,0	4,0	14,5	23,3	31,8	38,8	43,8	0,4	
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	2,2	2,5	0	0	< 0,1	
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	0	2,9	1,9	0	0	1,5	< 0,1	
C69	Oko in očesni adneksi Eye and adnexa	M	1,0	1,8	0	0	0	0	0	0	0	0	0	0	1,3	2,9	4,3	0	10,2	3,5	0,1	
		Ž	1,3	1,9	2,1	0	0	0	0	0	0	0	1,3	1,3	4,0	1,5	3,9	2,0	2,3	3,0	0,1	
C70	Meninge Meninges	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,4	3,5	0,0	
		Ž	0,1	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0	0	0	0	< 0,1	
C71	Možgani Brain	M	8,6	3,5	4,0	0	4,0	1,7	1,4	2,5	3,7	9,2	8,8	12,8	6,5	20,5	13,0	19,9	37,4	24,8	0,6	
		Ž	7,0	3,7	2,1	2,3	2,1	1,8	0	1,4	6,8	7,1	3,9	4,0	8,0	13,1	9,7	17,9	22,8	16,6	0,4	
C72	Hrbtani mozeg, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	0,2	0	2,0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0	0	< 0,1	
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C73	Ščitnica Thyroid gland	M	4,3	0	0	0	0	3,4	1,4	2,5	1,2	7,9	3,8	7,7	7,8	5,8	10,9	12,4	0	10,6	0,3	
		Ž	11,2	0	0	0	6,3	5,4	12,1	10,9	23,1	15,6	13,0	16,0	13,3	21,8	7,8	6,0	13,7	9,1	0,8	
C74	Nadledvična žleza Adrenal gland	M	0,3	0	0	0	0	0	0	0	0	1,3	0	0	0	1,5	0	0	0	3,5	< 0,1	
		Ž	0,3	3,7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,5	< 0,1	
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	< 0,1	
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	0,4	0	0	0	0	0	0	0	0	0	0	0	0	0	4,3	0	0	7,1	< 0,1	
		Ž	2,5	0	0	0	0	0	0	0	0	1,4	0	0	1,3	4,4	1,9	7,9	6,8	19,6	0,1	
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	1,8	0	0	0	0	0	0	0	1,2	1,3	1,3	3,9	1,3	7,3	6,5	5,0	3,4	0	0,1	
		Ž	1,2	0	0	0	0	0	0	0	0	0	1,3	2,7	0	0	1,9	4,0	2,3	7,5	< 0,1	

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M Ž	4,0 4,8	0 0	0 0	0 0	0 0	0 0	0 1,5	0 1,4	0 0	0 1,4	0 0	1,3 1,3	1,3 0	2,9 4,4	8,7 5,8	9,9 4,0	30,6 22,8	70,9 42,3	0,1 0,1	
	Metastaze, drugje Metastases of other sites	M Ž	1,4 1,4	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1,3 0	0 1,3	2,6 0	2,9 1,5	0 1,9	5,0 6,0	10,2 4,6	14,2 10,6	0,1 0,1	
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M Ž	4,7 5,8	0 0	0 0	0 0	0 0	0 0	0 0	0 1,4	1,2 0	0 4,3	0 1,3	2,6 2,7	10,4 4,0	10,2 4,4	10,9 5,8	14,9 21,8	27,2 22,8	39,0 34,7	0,3 0,2	
	Hodgkinova bolezen Hodgkin's disease	M Ž	2,3 2,0	0 0	0 0	0 4,5	6,0 6,3	3,4 3,6	2,8 3,0	2,5 1,4	2,5 4,1	4,0 0	0 0	1,3 1,3	2,6 1,3	2,9 0	0 0	0 4,0	3,4 4,6	10,6 3,0	0,1 0,1	
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M Ž	3,9 6,3	0 0	0 0	0 0	0 0	0 0	0 1,5	0 0	0 8,2	1,3 0	1,3 2,6	5,1 12,0	3,9 14,6	17,5 21,8	13,0 7,8	17,4 7,9	10,2 13,7	10,6 10,6	0,3 0,4	
	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M Ž	10,7 9,4	1,8 0	8,0 0	0 0	2,0 0	0 0	0 1,5	2,5 2,7	2,5 5,4	4,0 2,8	5,0 1,3	14,1 10,6	15,6 10,6	14,6 7,3	28,2 11,7	34,8 29,8	68,1 47,9	42,5 37,7	0,7 0,4	
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M Ž	2,0 1,6	0 0	0 2,1	2,1 0	0 0	0 0	0 0	0 0	1,2 1,4	0 4,3	1,3 2,6	3,9 0	0 1,3	2,9 0	2,2 0	9,9 2,0	13,6 6,8	10,6 7,5	0,1 0,1	
	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M Ž	1,4 1,1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1,2 0	0 0	0 0	0 0	3,9 0	2,9 1,5	4,3 0	2,5 0	17,0 4,6	0 12,1	0,1 < 0,1	
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M Ž	0,2 0,0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1,5 0	0 0	0 0	0 0	3,5 0	< 0,1 0,0	
	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M Ž	6,2 7,1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1,2 0	0 2,8	1,3 1,3	3,9 6,7	7,8 9,3	11,7 10,2	19,5 15,5	32,3 23,8	23,8 38,8	53,1 22,6	0,4 0,3	
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M Ž	1,6 0,4	7,0 0	6,0 2,1	2,1 0	4,0 0	0 0	1,4 0	0 0	1,2 0	1,3 0	0 0	0 1,3	0 0	2,9 0	2,2 0	0 2,0	0 2,3	0 0	0,1 < 0,1	
	Limfatična levkemija, druga Lymphoid leukaemia, other	M Ž	6,0 3,0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1,2 1,4	0 0	0 1,3	1,3 1,3	10,4 5,3	11,7 2,9	26,1 9,7	27,3 2,0	30,6 16,0	39,0 13,6	0,4 0,1	
C92	Mieloična levkemija Myeloid leukaemia	M Ž	5,9 6,0	1,8 1,9	0 0	0 6,8	0 0	1,7 3,6	1,4 0	1,2 1,4	0 1,4	2,6 1,4	3,8 3,9	3,9 2,7	6,5 6,7	5,8 10,2	17,4 11,7	29,8 21,8	30,6 11,4	35,4 21,1	0,4 0,4	
	Monocitna levkemija Monocytic leukaemia	M Ž	0,2 0,2	0 0	0 0	0 0	0 0	0 0	0 1,5	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	7,1 1,5	0,0 < 0,1	

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C94	Druge opredeljene levkemije	M	0,8	0	0	0	0	0	0	1,2	0	0	1,3	1,3	2,6	1,5	0	0	3,4	3,5	< 0,1
	Other leukaemias of specified cells	Ž	1,0	0	0	0	0	0	0	0	0	0	0	2,7	1,3	4,4	0	4,0	0	3,0	0,1
C95	Levkemija z neopredeljenim celičnim tipom	M	0,3	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	2,5	0	3,5	< 0,1
	Leukaemia, unspecified cell type	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	< 0,1
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	7,2	0	0	0	0	1,7	0	0	0	0	3,8	6,4	5,2	7,3	30,4	24,9	51,1	56,7	0,4
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	5,5	0	0	0	0	1,8	0	0	0	4,3	0	4,0	2,7	11,6	23,3	11,9	16,0	22,6	0,3

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
D03	Melanom, in situ	M	8,8	0	0	0	0	0	4,2	2,5	9,9	9,2	7,6	7,7	9,1	16,1	13,0	27,3	30,6	49,6	0,5
	Melanoma, in situ	Ž	8,0	0	0	0	0	1,8	3,0	5,4	4,1	7,1	13,0	6,7	16,0	13,1	21,4	19,9	11,4	9,1	0,6
D05	Dojka, in situ	M	0,2	0	0	0	0	0	0	0	0	0	0	0	1,3	1,5	0	0	0	0	< 0,1
	Breast, in situ	Ž	10,0	0	0	0	0	0	0	0	6,8	2,8	18,2	25,3	17,3	29,1	31,1	17,9	6,8	4,5	0,7
D06	Maternični vrat, CIN III	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
	Cervix uteri, in situ	Ž	100,8	0	0	0	6,3	182,3	301,1	293,7	235,1	184,6	103,0	70,5	43,9	46,5	31,1	7,9	16,0	3,0	7,5
D09.0	Sečni mehur, in situ	M	14,0	0	0	0	0	0	0	2,5	2,5	2,6	6,3	12,8	18,2	29,2	56,5	64,6	54,5	70,9	1,0
	Bladder, in situ	Ž	3,8	0	0	0	0	0	0	0	0	1,4	1,3	2,7	4,0	11,6	15,5	7,9	6,8	13,6	0,2
D32.0, D42.0	Meninge, benigna neoplazma	M	2,5	0	0	0	0	0	0	0	0	2,6	3,8	9,0	1,3	2,9	4,3	7,5	6,8	10,6	0,2
	Benign neoplasm of meninges	Ž	6,8	0	0	0	0	0	0	2,7	6,8	5,7	10,4	5,3	2,7	16,0	15,5	15,9	13,7	19,6	0,4
D33.0 – D33.2	Meninge, benigna neoplazma in negotovega značaja	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,5	0,0
	Benign neoplasm and neoplasm of uncertain behaviour of meninges	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	2,9	0	0	0	0	< 0,1
D39.1	Jajčnik, neopl. negotovega značaja	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
	Ovary, neopl. of uncertain behavior	Ž	5,4	0	0	0	0	5,4	3,0	4,1	5,4	2,8	6,5	8,0	13,3	10,2	7,8	13,9	4,6	1,5	0,4
D43.0 – D43.2	Možgani, neopredeljeno	M	0,3	1,8	0	0	0	0	0	0	1,2	0	0	0	0	0	0	0	3,4	0	< 0,1
	CNS, uncertain or unknown	Ž	0,6	1,9	0	0	0	0	0	0	1,4	0	0	0	0	0	0	0	4,6	3,0	< 0,1

Tabela 6a: Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2013.

Table 6a: Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2013.

Statistična regija Statistical region	Spol Sex	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)											
		C00–C96	C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06
Slovenija, skupaj Slovenia, total	M	7442	298	436	71	310	869	1350	13	—	—	1485	2610	—
	Ž	6275	178	350	54	154	429	1336	1252	124	311	—	2087	1048
Pomurska	M	478	17	24	7	35	41	78	0	—	—	132	144	—
	Ž	366	16	23	6	18	15	79	64	8	20	—	117	82
Podravska	M	1071	56	77	14	59	145	119	2	—	—	184	415	—
	Ž	861	36	51	7	18	60	129	204	20	53	—	283	265
Koroška	M	267	12	11	2	10	29	51	0	—	—	92	60	—
	Ž	224	6	17	2	6	11	49	55	8	10	—	60	31
Savinjska	M	841	41	59	15	39	99	137	3	—	—	145	303	—
	Ž	667	21	50	3	14	42	114	149	12	44	—	218	123
Zasavska	M	168	8	11	2	8	31	14	0	—	—	21	73	—
	Ž	160	2	7	9	8	22	17	27	3	7	—	58	18
Spodnjeposavska	M	249	14	17	3	17	16	34	2	—	—	61	85	—
	Ž	198	9	6	2	5	17	45	31	2	16	—	65	25
Jugovzhodna Slovenija	M	535	13	35	10	19	64	100	0	—	—	99	195	—
	Ž	425	7	22	4	10	26	107	85	7	15	—	142	48
Osrednjeslovenska	M	1987	76	83	6	70	211	462	4	—	—	386	689	—
	Ž	1821	48	90	15	39	123	464	341	34	68	—	599	227
Gorenjska	M	768	27	52	4	19	93	147	0	—	—	165	261	—
	Ž	684	12	42	1	16	43	160	117	13	23	—	257	121
Notranjsko-kraška	M	187	7	12	1	3	25	33	0	—	—	36	70	—
	Ž	149	4	9	0	1	6	32	30	8	9	—	50	23
Goriška	M	450	12	28	3	17	57	82	1	—	—	89	161	—
	Ž	362	9	17	2	8	32	60	74	4	30	—	126	27
Obalno-kraška	M	441	15	27	4	14	58	93	1	—	—	75	154	—
	Ž	358	8	16	3	11	32	80	75	5	16	—	112	58

Opis šifer MKB/Description of the ICD code

C16 Želodec
StomachC18 Debelo črevo
ColonC19 Rektosigmoidna zveza
Rectosigmoid junctionC20 Rektum
RectumC34 Sapnica in pljuča
Bronchus and lungC44 Koža, razen melanoma
Skin, non-melanomaC50 Dojka
BreastC53 Maternični vrat
Cervix uteriC54 Maternično telo
Corpus uteriC61 Prostata
ProstateD06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

Tabela 6b: Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2013.

Table 6b: Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2013.

Statistična regija Statistical region	Spol Sex	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)											
		C00–C96	C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06
Slovenija, skupaj Slovenia, total	M	695,0	27,8	41,2	6,5	28,5	79,3	127,8	1,2	—	—	139,6	267,9	—
	Ž	471,4	12,4	24,8	3,6	10,8	32,4	93,9	102,2	10,9	23,7	—	187,0	111,1
Pomurska	M	755,4	23,7	41,1	10,3	53,8	61,9	124,4	0,0	—	—	212,5	243,1	—
	Ž	461,9	20,5	31,9	7,8	18,5	18,6	86,4	90,2	12,4	25,1	—	166,9	156,7
Podravska	M	612,9	33,9	45,5	8,2	33,3	79,3	70,2	1,1	—	—	103,0	260,1	—
	Ž	399,8	15,1	23,6	2,7	7,8	29,8	54,2	103,5	10,3	24,5	—	151,6	179,9
Koroška	M	691,4	31,7	28,4	4,6	28,4	71,8	137,0	0,0	—	—	236,5	182,9	—
	Ž	499,8	9,4	36,8	3,6	12,8	22,9	103,3	129,6	24,6	22,4	—	144,6	101,2
Savinjska	M	628,4	29,3	46,1	11,2	28,4	72,3	105,8	2,2	—	—	107,7	234,0	—
	Ž	412,2	12,4	27,2	1,2	7,8	26,0	68,8	98,0	8,7	26,7	—	152,5	105,4
Zasavska	M	708,6	29,4	49,2	8,1	33,8	129,4	56,0	0,0	—	—	87,5	337,6	—
	Ž	512,5	5,1	17,3	28,1	24,9	73,5	51,8	91,7	9,0	22,8	—	219,5	97,8
Spodnjeposavska	M	653,2	38,5	44,9	6,8	41,9	40,1	87,4	5,0	—	—	165,0	231,0	—
	Ž	431,5	17,1	8,8	4,1	11,6	38,4	95,2	75,7	5,7	38,6	—	172,3	77,2
Jugovzhodna Slovenija	M	756,5	18,0	50,4	14,2	26,0	91,4	141,9	0,0	—	—	141,8	298,9	—
	Ž	476,1	7,0	27,7	4,5	8,7	28,9	113,3	104,7	8,0	19,0	—	180,4	77,3
Osrednjeslovenska	M	750,1	28,4	31,2	2,1	26,0	79,4	175,3	1,5	—	—	148,8	291,2	—
	Ž	531,6	13,0	24,8	3,4	11,7	35,7	126,8	108,4	10,9	20,2	—	227,4	86,8
Gorenjska	M	725,2	26,2	49,4	3,7	17,8	86,5	138,8	0,0	—	—	157,0	275,5	—
	Ž	523,6	8,3	29,4	0,9	10,8	32,9	115,8	95,6	12,8	18,4	—	226,9	131,4
Notranjsko-kraška	M	648,4	22,2	39,8	3,1	10,8	84,2	113,3	0,0	—	—	131,9	265,5	—
	Ž	435,8	10,7	19,5	0,0	2,9	19,8	91,7	96,9	31,7	25,6	—	174,7	95,1
Goriška	M	664,3	17,4	38,7	4,5	24,4	82,1	120,5	1,6	—	—	136,0	265,5	—
	Ž	451,5	12,7	18,2	2,5	9,5	38,0	61,4	101,1	5,8	37,1	—	191,6	48,3
Obalno-kraška	M	711,1	22,3	44,1	6,0	22,2	89,5	153,9	1,6	—	—	121,5	285,3	—
	Ž	480,1	8,9	19,5	3,7	13,7	42,5	109,2	108,3	7,9	19,8	—	164,4	114,2

Opis šifer MKB/Description of the ICD code

C16 Želodec
Stomach

C18 Debelo črevo
Colon

C19 Rektosigmoidna zveza
Rectosigmoid junction

C20 Rektum
Rectum

C34 Sapnica in pljuča
Bronchus and lung

C44 Koža, razen melanoma
Skin, non-melanoma

C50 Dojka
Breast

C53 Maternični vrat
Cervix uteri

C54 Maternično telo
Corpus uteri

C61 Prostata
Prostate

D06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Standard – prebivalstvo Slovenije po popisu 2002

* Standard – population of Slovenia according to census 2002

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2013.

Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2013.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C00		C01		C02		C03		C04		C05		C06		C07		C08		C09	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12290	607	18	2	17	1	27	0	12	0	34	1	18	0	19	0	9	0	4	1	52	0
Small cell carcinoma	182	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	58	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1382	58	17	2	17	1	27	–	12	–	32	1	13	–	18	–	–	–	–	–	50	–
Basal cell carcinoma	2171	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	365	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6107	201	1	–	–	–	–	–	–	–	–	–	1	–	–	–	6	–	3	1	–	–
Other specified carcinomas	91	2	–	–	–	–	–	–	–	–	2	–	4	–	–	–	3	–	1	–	1	–
Carcinoma, unspecified	84	150	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Malignant thymoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	556	6	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–
Fibrosarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	19	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	17	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	20	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	61	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	37	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	57	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	43	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	128	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	352	24	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	43	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	122	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	70	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	126	31	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	66	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	56	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	5	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C10		C11		C12		C13		C14		C15		C16		C17		C18		C19	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12290	607	42	0	15	1	32	0	28	0	0	0	68	2	455	5	30	1	744	3	118	0
Small cell carcinoma	182	23	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—
Non-small cell carcinoma	58	21	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Squamous cell carcinoma	1382	58	39	—	13	1	31	—	27	—	—	—	45	—	2	—	—	—	—	—	—	—
Basal cell carcinoma	2171	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Transitional cell carcinoma	365	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Adenocarcinoma	6107	201	—	—	—	—	1	—	—	—	—	—	18	1	423	1	21	—	733	2	114	—
Other specified carcinomas	91	2	2	—	1	—	—	—	1	—	—	—	1	—	1	—	—	—	3	—	1	—
Carcinoma, unspecified	84	150	1	—	1	—	—	—	—	—	—	—	3	1	3	4	—	1	6	1	3	—
Malignant thymoma	4	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant paraganglioma/pheochromocytoma	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant melanoma	556	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fibrosarcoma	10	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fibrohistiocytic sarcoma	10	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Liposarcoma	19	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leiomyosarcoma	17	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—
Rhabdomyosarcoma	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Synovial sarcoma	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Angiosarcoma	4	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kaposi sarcoma	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Osteosarcoma	9	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chondrosarcoma	7	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ewing sarcoma/PNET	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified sarcomas	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sarcoma, unspecified	20	1	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—
Malignant complex mixed and stromal tumors	61	1	—	—	—	—	—	—	—	—	—	—	1	—	24	—	8	—	1	—	—	—
Malignant fibroepithelial tumors	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant mesothelioma	37	5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gonadal stromal tumors	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dysgerminoma and seminoma	57	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other malignant germ cell tumors	43	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant trophoblastic tumors	4	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gliomas	128	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant neuroepithelial tumors	4	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant meningioma	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant nerve sheath tumors	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non Hodgkin lymphoma	352	24	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hodgkin lymphoma	43	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Plasma cell tumors	122	15	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic lymphoid leukemia	70	16	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukemia except chronic lymphoid	126	31	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other lymphoreticular neoplasms	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic myeloproliferative diseases	66	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myelodysplastic syndromes	56	20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified malignant tumors	3	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant tumor, unspecified	5	5	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
	C00–C96		C20		C21		C22		C23		C24		C25		C26		C30		C31		C32					
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C				
Vse vrste/All types	12290	607	452	3	7	0	62	22	50	1	45	16	159	43	0	0	4	0	6	1	97	3				
Small cell carcinoma	182	23	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–					
Non-small cell carcinoma	58	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Squamous cell carcinoma	1382	58	1	–	5	–	–	–	–	–	–	–	–	–	–	–	1	–	2	1	96	1				
Basal cell carcinoma	2171	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Transitional cell carcinoma	365	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Adenocarcinoma	6107	201	434	1	2	–	60	21	47	–	44	10	148	30	–	–	2	–	1	–	–	–				
Other specified carcinomas	91	2	1	–	–	–	–	–	–	–	1	–	3	–	–	–	–	–	1	–	–	–				
Carcinoma, unspecified	84	150	13	2	–	–	1	1	3	1	–	3	8	12	–	–	–	–	1	–	1	2				
Malignant thymoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant paraganglioma/pheochromocytoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant melanoma	556	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–					
Fibrosarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Fibrohistiocytic sarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Liposarcoma	19	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Leiomyosarcoma	17	2	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–					
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Synovial sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Osteosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Ewing sarcoma/PNET	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Sarcoma, unspecified	20	1	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant complex mixed and stromal tumors	61	1	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant mesothelioma	37	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant gonadal stromal tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Dysgerminoma and seminoma	57	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Other malignant germ cell tumors	43	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant trophoblastic tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant gliomas	128	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant neuroepithelial tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant meningioma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant nerve sheath tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Non Hodgkin lymphoma	352	24	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Hodgkin lymphoma	43	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Plasma cell tumors	122	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Chronic lymphoid leukemia	70	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Leukemia except chronic lymphoid	126	31	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Chronic myeloproliferative diseases	66	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Myelodysplastic syndromes	56	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Other specified malignant tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–					
Malignant tumor, unspecified	5	5	–	–	–	–	1	–	–	–	–	2	–	1	–	–	–	–	–	–	–					

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C33		C34		C37		C38		C39		C40		C41		C43		C44		C45	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12290	607	1	0	1025	163	4	0	6	0	0	0	7	0	13	0	521	3	2638	29	37	5
Small cell carcinoma	182	23	—	—	171	22	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non-small cell carcinoma	58	21	—	—	57	21	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Squamous cell carcinoma	1382	58	1	—	314	33	—	—	—	—	—	—	—	—	—	—	—	—	436	16	—	—
Basal cell carcinoma	2171	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2165	11	—	—
Transitional cell carcinoma	365	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Adenocarcinoma	6107	201	—	—	443	77	—	—	—	—	—	—	—	—	—	—	—	—	18	1	—	—
Other specified carcinomas	91	2	—	—	27	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Carcinoma, unspecified	84	150	—	—	10	9	—	—	—	—	—	—	—	—	—	—	—	—	8	1	—	—
Malignant thymoma	4	0	—	—	—	—	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant paraganglioma/pheochromocytoma	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant melanoma	556	6	—	—	—	—	—	—	—	—	—	—	—	—	—	521	3	—	—	—	—	—
Fibrosarcoma	10	0	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fibrohistiocytic sarcoma	10	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	8	—	—	—	—
Liposarcoma	19	1	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—
Leiomyosarcoma	17	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—
Rhabdomyosarcoma	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Synovial sarcoma	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Angiosarcoma	4	0	—	—	—	—	—	—	1	—	—	—	—	—	1	—	—	—	—	—	—	—
Kaposi sarcoma	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Osteosarcoma	9	0	—	—	—	—	—	—	—	—	—	—	5	—	4	—	—	—	—	—	—	—
Chondrosarcoma	7	0	—	—	1	—	—	—	—	—	—	—	1	—	4	—	—	—	—	—	—	—
Ewing sarcoma/PNET	2	0	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—
Other specified sarcomas	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sarcoma, unspecified	20	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—
Malignant complex mixed and stromal tumors	61	1	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	1	—	—	—
Malignant fibroepithelial tumors	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant mesothelioma	37	5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	37	5
Malignant gonadal stromal tumors	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dysgerminoma and seminoma	57	0	—	—	—	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—
Other malignant germ cell tumors	43	0	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant trophoblastic tumors	4	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gliomas	128	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant neuroepithelial tumors	4	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant meningioma	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant nerve sheath tumors	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non Hodgkin lymphoma	352	24	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hodgkin lymphoma	43	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Plasma cell tumors	122	15	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic lymphoid leukemia	70	16	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukemia except chronic lymphoid	126	31	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other lymphoreticular neoplasms	2	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic myeloproliferative diseases	66	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myelodysplastic syndromes	56	20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified malignant tumors	3	0	—	—	—	—	—	—	—	—	—	—	—	—	3	—	—	—	—	—	—	—
Malignant tumor, unspecified	5	5	—	—	1	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C46		C47		C48		C49		C50		C51		C52		C53		C54		C55	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12290	607	1	0	3	0	23	2	44	2	1165	91	42	0	11	0	124	0	309	0	15	0
Small cell carcinoma	182	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–
Non-small cell carcinoma	58	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1382	58	–	–	–	–	–	–	–	–	2	–	35	–	8	–	100	–	–	–	1	–
Basal cell carcinoma	2171	11	–	–	–	–	–	–	–	–	–	–	5	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	365	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–
Adenocarcinoma	6107	201	–	–	–	–	14	1	–	–	1155	14	–	–	–	–	19	–	277	–	–	–
Other specified carcinomas	91	2	–	–	–	–	–	–	–	–	7	–	–	–	–	–	4	–	17	–	1	–
Carcinoma, unspecified	84	150	–	–	–	–	–	–	–	–	–	77	1	–	1	–	–	–	–	–	–	–
Malignant thymoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	556	6	–	–	–	–	–	–	–	–	–	–	1	–	–	–	1	–	–	–	–	–
Fibrosarcoma	10	0	–	–	–	–	–	–	8	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	10	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	19	1	–	–	–	–	5	1	13	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	17	2	–	–	–	–	2	–	3	1	–	–	–	–	–	–	–	–	2	–	7	–
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	2	0	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	4	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	7	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	2	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	20	1	–	–	–	–	2	–	12	1	–	–	–	–	–	–	–	–	–	–	2	–
Malignant complex mixed and stromal tumors	61	1	–	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	10	–	4	–
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	37	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	57	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	43	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–
Malignant gliomas	128	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	4	0	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	2	0	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	352	24	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	43	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	122	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	70	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	126	31	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	66	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	56	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	5	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
			C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12290	607	157	13	14	1	0	0	11	0	1439	1	96	0	3	0	314	13	36	4	19	0				
Small cell carcinoma	182	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	58	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1382	58	–	–	–	–	–	–	11	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–
Basal cell carcinoma	2171	11	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	365	9	2	–	–	–	–	–	–	–	4	–	–	–	–	–	–	–	–	35	4	19	–	–	–	–
Adenocarcinoma	6107	201	146	6	14	1	–	–	–	–	1433	1	–	–	–	–	309	7	–	–	–	–	–	–	–	–
Other specified carcinomas	91	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	84	150	1	7	–	–	–	–	–	–	2	–	–	–	–	–	1	5	–	–	–	–	–	–	–	–
Malignant thymoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	556	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	10	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	19	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	17	2	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	20	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	61	1	4	–	–	–	–	–	–	–	–	–	–	–	–	–	3	1	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	37	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	57	0	1	–	–	–	–	–	–	–	–	–	–	53	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	43	0	2	–	–	–	–	–	–	–	–	–	–	40	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	3	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	128	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	352	24	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	43	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	122	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	70	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	126	31	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	66	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	56	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	5	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
	C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75		C76					
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C				
Vse vrste/All types	12290	607	313	14	6	0	22	0	3	0	127	1	2	0	154	5	6	0	1	0	7	3				
Small cell carcinoma	182	23	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–				
Non-small cell carcinoma	58	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Squamous cell carcinoma	1382	58	6	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Basal cell carcinoma	2171	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Transitional cell carcinoma	365	9	298	5	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Adenocarcinoma	6107	201	2	–	1	–	–	–	–	–	–	–	–	–	149	2	2	–	–	–	5	2				
Other specified carcinomas	91	2	1	–	–	–	–	–	–	–	–	–	–	–	4	1	1	–	–	–	–	–				
Carcinoma, unspecified	84	150	3	9	–	–	–	–	–	–	–	–	–	–	1	2	–	–	1	–	–	1				
Malignant thymoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant paraganglioma/pheochromocytoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–				
Malignant melanoma	556	6	–	–	–	–	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Fibrosarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Fibrohistiocytic sarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Liposarcoma	19	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Leiomyosarcoma	17	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Rhabdomyosarcoma	1	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Synovial sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Osteosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Ewing sarcoma/PNET	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Sarcoma, unspecified	20	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant complex mixed and stromal tumors	61	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant mesothelioma	37	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant gonadal stromal tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–				
Dysgerminoma and seminoma	57	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other malignant germ cell tumors	43	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant trophoblastic tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant gliomas	128	1	–	–	–	–	–	–	–	–	126	1	2	–	–	–	–	–	–	–	–	–				
Malignant neuroepithelial tumors	4	0	–	–	–	–	–	–	–	–	1	–	–	–	–	–	2	–	–	–	–	–				
Malignant meningioma	2	0	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant nerve sheath tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Non Hodgkin lymphoma	352	24	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Hodgkin lymphoma	43	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Plasma cell tumors	122	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chronic lymphoid leukemia	70	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Leukemia except chronic lymphoid	126	31	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chronic myeloproliferative diseases	66	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Myelodysplastic syndromes	56	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other specified malignant tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant tumor, unspecified	5	5	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–				

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
	C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85		C88					
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C				
Vse vrste/All types	12290	607	25	4	27	14	9	2	49	21	43	1	101	4	195	12	37	0	17	8	2	0				
Small cell carcinoma	182	23	1	–	–	–	–	–	2	1	–	–	–	–	–	–	–	–	–	–	–	–				
Non-small cell carcinoma	58	21	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–				
Squamous cell carcinoma	1382	58	15	1	–	–	1	–	2	1	–	–	–	–	–	–	–	–	–	–	–	–				
Basal cell carcinoma	2171	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Transitional cell carcinoma	365	9	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–				
Adenocarcinoma	6107	201	5	3	21	10	8	2	27	7	–	–	–	–	–	–	–	–	–	–	–	–				
Other specified carcinomas	91	2	–	–	1	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–				
Carcinoma, unspecified	84	150	3	–	3	4	–	–	4	7	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant thymoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant paraganglioma/pheochromocytoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant melanoma	556	6	–	–	2	–	–	–	9	3	–	–	–	–	–	–	–	–	–	–	–	–				
Fibrosarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Fibrohistiocytic sarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Liposarcoma	19	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Leiomyosarcoma	17	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Synovial sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Osteosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Ewing sarcoma/PNET	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Sarcoma, unspecified	20	1	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant complex mixed and stromal tumors	61	1	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant mesothelioma	37	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant gonadal stromal tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Dysgerminoma and seminoma	57	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other malignant germ cell tumors	43	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant trophoblastic tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant gliomas	128	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant neuroepithelial tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant meningioma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant nerve sheath tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Non Hodgkin lymphoma	352	24	–	–	–	–	–	–	–	–	–	–	101	4	195	12	37	–	17	8	2	–				
Hodgkin lymphoma	43	1	–	–	–	–	–	–	–	–	43	1	–	–	–	–	–	–	–	–	–	–				
Plasma cell tumors	122	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chronic lymphoid leukemia	70	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Leukemia except chronic lymphoid	126	31	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Chronic myeloproliferative diseases	66	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Myelodysplastic syndromes	56	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Other specified malignant tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–				
Malignant tumor, unspecified	5	5	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–				

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)													
	C00–C96		C90		C91		C92		C93		C94		C95		C96	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12290	607	122	15	87	25	104	18	3	1	18	0	1	3	107	23
Small cell carcinoma	182	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	58	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1382	58	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	2171	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	365	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6107	201	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	91	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	84	150	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	556	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	10	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	19	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	17	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	20	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	61	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	37	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	57	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	43	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	128	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	352	24	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	43	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	122	15	122	15	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	70	16	–	–	70	16	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	126	31	–	–	17	9	104	18	3	1	1	–	1	3	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	2	–
Chronic myeloproliferative diseases	66	3	–	–	–	–	–	–	–	–	17	–	–	–	49	3
Myelodysplastic syndromes	56	20	–	–	–	–	–	–	–	–	–	–	–	–	56	20
Other specified malignant tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	5	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2013.

Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2013.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznano	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C00	Vse lokacije	M+Ž	12733	6936	54,5	3350	26,3	2319	18,2	128	1,0
C80	All sites	M	6927	3717	53,7	1848	26,7	1286	18,6	76	1,1
		Ž	5806	3219	55,4	1502	25,9	1033	17,8	52	0,9
C00	Ustnica	M	13	11	—	2	—	0	—	0	—
	Lip	Ž	8	6	—	2	—	0	—	0	—
C01	Baza jezika	M	15	4	26,7	11	73,3	0	0	0	0
	Base of tongue	Ž	3	0	—	3	—	0	—	0	—
C02	Jezik, drugi deli	M	23	8	34,8	15	65,2	0	0	0	0
	Tongue, other & unspecified parts	Ž	4	2	—	2	—	0	—	0	—
C03	Dlesen	M	6	3	—	3	—	0	—	0	—
	Gum	Ž	6	2	—	4	—	0	—	0	—
C04	Ustno dno	M	29	13	44,8	15	51,7	1	3,4	0	0
	Floor of mouth	Ž	6	3	—	3	—	0	—	0	—
C05	Nebo	M	11	6	—	5	—	0	—	0	—
	Palate	Ž	7	3	—	4	—	0	—	0	—
C06	Usta, drugi deli	M	14	2	—	12	—	0	—	0	—
	Mouth, other & unspecified parts	Ž	5	2	—	3	—	0	—	0	—
C07	Parotidna žleza	M	6	4	—	2	—	0	—	0	—
	Parotid gland	Ž	3	1	—	2	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke	M	3	2	—	0	—	1	—	0	—
	Other & unspecified major salivary glands	Ž	2	1	—	0	—	1	—	0	—
C09	Tonzila	M	40	4	10,0	35	87,5	1	2,5	0	0
	Tonsil	Ž	12	1	—	11	—	0	—	0	—
C10	Orofarinks	M	38	3	7,9	33	86,8	0	0	2	5,3
	Oropharynx	Ž	5	0	—	5	—	0	—	0	—
C11	Nazofarinks	M	13	0	—	13	—	0	—	0	—
	Nasopharynx	Ž	3	1	—	2	—	0	—	0	—
C12	Piriformni sinus	M	29	2	6,9	24	82,8	3	10,3	0	0
	Pyiform sinus	Ž	3	1	—	2	—	0	—	0	—
C13	Hipofarinks	M	30	2	6,7	23	76,7	4	13,3	1	3,3
	Hypopharynx	Ž	1	0	—	1	—	0	—	0	—
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinku	M	1	0	—	1	—	0	—	0	—
	Other and ill-defined sites in the lip, oral cavity and pharynx	Ž	0	0	—	0	—	0	—	0	—
C15	Požiralnik	M	64	11	17,2	35	54,7	14	21,9	4	6,3
	Oesophagus	Ž	12	2	—	5	—	3	—	2	—
C16	Želodec	M	297	69	23,2	133	44,8	90	30,3	5	1,7
	Stomach	Ž	178	39	21,9	63	35,4	72	40,4	4	2,2
C17	Tanko črevo	M	16	8	50,0	7	43,8	1	6,3	0	0
	Small intestine	Ž	15	4	26,7	4	26,7	7	46,7	0	0
C18	Debelo črevo	M	436	82	18,8	256	58,7	91	20,9	7	1,6
	Colon	Ž	350	42	12,0	217	62,0	89	25,4	2	0,6
C19	Rektosigmoidna zveza	M	71	12	16,9	38	53,5	19	26,8	2	2,8
	Rectosigmoid junction	Ž	53	6	11,3	33	62,3	12	22,6	2	3,8
C20	Rektum	M	310	64	20,6	163	52,6	74	23,9	9	2,9
	Rectum	Ž	153	41	26,8	76	49,7	29	19,0	7	4,6
C21	Anus in analni kanal	M	1	1	—	0	—	0	—	0	—
	Anus and anal canal	Ž	6	4	—	2	—	0	—	0	—
C22	Jetra in intrahepatični vodi	M	139	54	38,8	38	27,3	40	28,8	7	5,0
	Liver and intrahepatic bile ducts	Ž	47	16	34,0	7	14,9	21	44,7	3	6,4
C23	Žolčnik	M	20	2	10,0	7	35,0	11	55,0	0	0
	Gallbladder	Ž	52	10	19,2	21	40,4	21	40,4	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta	M	52	13	25,0	21	40,4	16	30,8	2	3,8
	Biliary tract, other and unspecified parts	Ž	52	16	30,8	18	34,6	17	32,7	1	1,9
C25	Trebušna slinavka	M	183	15	8,2	57	31,1	111	60,7	0	0
	Pancreas	Ž	166	22	13,3	59	35,5	82	49,4	3	1,8
C26	Druga in slabo opredeljena mesta v prebavnih organih	M	0	0	—	0	—	0	—	0	—
	Other and ill-defined digestive organs	Ž	0	0	—	0	—	0	—	0	—

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznani	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	4	0	—	4	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	4	0	—	4	—	0	—	0	—
		Ž	4	0	—	4	—	0	—	0	—
C32	Grlo Larynx	M	83	37	44,6	43	51,8	3	3,6	0	0
		Ž	18	9	50,0	8	44,4	1	5,6	0	0
C33	Sapnik Trachea	M	0	0	—	0	—	0	—	0	—
		Ž	1	0	—	1	—	0	—	0	—
C34	Sapnica in pljuča Bronchus and lung	M	863	118	13,7	245	28,4	497	57,6	3	0,3
		Ž	425	70	16,5	135	31,8	217	51,1	3	0,7
C37	Timus Thymus	M	2	0	—	1	—	1	—	0	—
		Ž	2	0	—	2	—	0	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	7	3	—	3	—	0	—	1	—
		Ž	2	1	—	1	—	0	—	0	—
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	4	3	—	1	—	0	—	0	—
		Ž	3	1	—	0	—	2	—	0	—
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	6	2	—	4	—	0	—	0	—
		Ž	7	3	—	3	—	1	—	0	—
C43	Maligni melanom kože Malignant melanoma of skin	M	274	208	75,9	57	20,8	8	2,9	1	0,4
		Ž	250	212	84,8	36	14,4	1	0,4	1	0,4
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1350	1335	98,9	15	1,1	0	0	0	0
		Ž	1336	1326	99,3	10	0,7	0	0	0	0
C45	Mezoteliom Mesothelioma	M	30	13	43,3	13	43,3	4	13,3	0	0
		Ž	12	4	—	4	—	2	—	2	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	1	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	2	1	—	1	—	0	—	0	—
		Ž	1	0	—	1	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	5	0	—	4	—	1	—	0	—
		Ž	20	0	0	10	50,0	10	50,0	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	28	10	35,7	12	42,9	5	17,9	1	3,6
		Ž	18	4	22,2	13	72,2	1	5,6	0	0
C50	Dojka Breast	M	13	4	—	9	—	0	—	0	—
		Ž	1250	694	55,5	479	38,3	76	6,1	1	0,1
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—
		Ž	43	21	48,8	21	48,8	1	2,3	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—
		Ž	11	4	—	6	—	1	—	0	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—
		Ž	124	53	42,7	52	41,9	18	14,5	1	0,8
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—
		Ž	311	234	75,2	59	19,0	16	5,1	2	0,6
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—
		Ž	17	3	17,6	6	35,3	7	41,2	1	5,9
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—
		Ž	177	18	10,2	11	6,2	145	81,9	3	1,7
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—
		Ž	15	1	6,7	5	33,3	9	60,0	0	0
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—
		Ž	0	0	—	0	—	0	—	0	—
C60	Penis Penis	M	11	8	—	2	—	1	—	0	—
		Ž	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1479	1037	70,1	331	22,4	100	6,8	11	0,7
		Ž	—	—	—	—	—	—	—	—	—

Nadaljevanje —>

Continued —>

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C62	Modo Testis	M	96	62	64,6	25	26,0	9	9,4	0	0
		Ž	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	3	—	0	—	0	—	0	—
		Ž	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	242	140	57,9	50	20,7	52	21,5	0	0
		Ž	123	84	68,3	18	14,6	21	17,1	0	0
C65	Ledvični meh Renal pelvis	M	24	5	20,8	13	54,2	6	25,0	0	0
		Ž	18	12	66,7	4	22,2	2	11,1	0	0
C66	Sečevod Ureter	M	14	11	—	2	—	1	—	0	—
		Ž	5	4	—	1	—	0	—	0	—
C67	Sečni mehur Bladder	M	253	193	76,3	40	15,8	18	7,1	2	0,8
		Ž	91	63	69,2	22	24,2	5	5,5	1	1,1
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	2	—	0	—	0	—	0	—
		Ž	4	3	—	1	—	0	—	0	—
C69	Oko in očesni adneksi Eye and adnexa	M	10	9	—	1	—	0	—	0	—
		Ž	14	7	—	7	—	0	—	0	—
C70	Meninge Meninges	M	2	2	—	0	—	0	—	0	—
		Ž	1	0	—	1	—	0	—	0	—
C71	Možgani Brain	M	87	86	98,9	0	0	1	1,1	0	0
		Ž	73	73	100	0	0	0	0	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli ČŽS Spinal cord, cranial nerves and other parts of CNS	M	2	2	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C73	Ščitnica Thyroid gland	M	44	27	61,4	14	31,8	3	6,8	0	0
		Ž	116	89	76,7	22	19,0	5	4,3	0	0
C74	Nadledvična žleza Adrenal gland	M	3	0	—	2	—	1	—	0	—
		Ž	3	0	—	1	—	2	—	0	—
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	—	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	3	0	—	3	—	0	—	0	—
		Ž	25	0	0	9	36,0	15	60,0	1	4,0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	18	0	0	0	0	0	0	18	100
		Ž	12	0	—	0	—	0	—	12	—
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	41	0	0	0	0	41	100	0	0
		Ž	49	0	0	0	0	49	100	0	0
C79	Metastaze, drugje Metastases of other sites	M	13	0	—	0	—	13	—	0	—
		Ž	15	0	0	0	0	15	100	0	0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	44	0	0	0	0	44	100	0	0
		Ž	57	0	0	0	0	57	100	0	0

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij (Ann–Arbor)							
				I		II		III+IV		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage (Ann–Arbor)							
				I		II		III+IV		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C81	Hodgkinova bolezen Hodgkin's disease	M	23	2	8,7	6	26,1	15	65,2	0	0
		Ž	21	0	0	8	38,1	9	42,9	4	19,0
C82–C85	Ne-Hodgkinov limfom Non-Hodgkin's lymphoma	M	183	41	22,4	29	15,8	81	44,3	32	17,5
		Ž	191	36	18,8	22	11,5	112	58,6	21	11,0

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 9: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2013.

Table 9: Incidence of non-Hodgkin's malignant lymphomas* by site, by sex and by age, Slovenia 2013.

Šifra MKB-8 ICD-8 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80+
	Vsi NHL All NHL	M+Ž	374	1	5	1	1	0	2	4	15	9	11	35	38	47	32	46	64	63
		M	183	1	4	1	1	0	0	2	4	4	6	18	18	26	22	26	32	18
		Ž	191	0	1	0	0	0	2	2	11	5	5	17	20	21	10	20	32	45
141	Jezik Tongue	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
142	Slinavke Salivary glands	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0
		Ž	3	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0
143	Dlesni Gum	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
144	Ustno dno Floor of mouth	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
145	Usta, drugo Mouth, other parts	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
146	Orofarinks Oropharynx	M	5	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	2
		Ž	5	0	0	0	0	0	0	0	0	1	0	0	0	1	0	2	1	0
147	Epifarinks Epipharynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
148	Hipofarinks Hypopharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
151	Želodec Stomach	M	12	0	0	0	0	0	0	0	1	0	0	0	2	1	3	3	1	1
		Ž	9	0	0	0	0	0	0	0	0	0	0	2	2	0	1	1	0	3
152	Tanko črevo Small intestine	M	2	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
153	Debelo črevo Colon	M	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	1
160	Nos, obnosne votline, drugo Nose, sinuses, etc.	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
162	Sapnik, sapnica, pljuča Trachea, bronchus, lung	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
170	Kosti Bone	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
171	Mehka tkiva Soft tissues	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
173	Koža, drugi malignomi Skin, other malignancies	M	6	0	0	0	0	0	0	0	0	1	0	0	0	1	2	1	0	1
		Ž	6	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	3
174	Dojka Breast	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
189	Ledvica, sečevod, drugo Kidney, ureter, etc.	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
190	Oko Eye	M	5	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1
		Ž	5	0	0	0	0	0	0	0	2	0	0	0	1	1	0	0	0	1
191	Možgani Brain	M	7	0	0	0	0	0	0	0	0	0	0	1	0	3	0	1	2	0
		Ž	5	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	1	1
194	Endokrine žleze, druge Endocrine glands, other	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
202	Bezgavke Lymph nodes	M	134	1	3	1	1	0	0	2	2	2	6	15	12	17	15	18	26	13
		Ž	141	0	1	0	0	0	2	2	6	2	5	14	17	15	7	14	28	28

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2013.

Table 10: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2013.

Šifra ICD-O-3 ICD-O-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
	Vse vrste All types	M+Ž	669	32,5
		M	348	34,1
		Ž	321	30,9
9727, 9728, 9835, 9836, 9811–9818	Neoplazme nezrelih celic B Precursor lymphoid neoplasms B	M	7	0,7
		Ž	3	0,3
9727, 9728, 9835, 9836, 9811	Limfoblastni limfom B / levkemija B, BDO B lymphoblastic lymphoma / leukaemia, NOS	M	5	0,5
		Ž	3	0,3
9812	Limfoblastni limfom B / levkemija B z rekurentnimi citogenetskimi anomalijami B lymphoblastic lymphoma / leukaemia with recurrent genetic abnormalities	M	2	0,2
		Ž	0	0,0
9729, 9837	Neoplazme nezrelih celic T Precursor lymphoid neoplasms T	M	7	0,7
		Ž	0	0,0
9729, 9837	Limfoblastni limfom T / levkemija T T lymphoblastic lymphoma / leukaemia	M	7	0,7
		Ž	0	0,0
9591–9597, 9670–9699, 9712, 9731–9738, 9760–9764, 9823, 9826, 9833, 9940	Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms	M	288	28,2
		Ž	275	26,5
9670, 9823	Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma	M	59	5,8
		Ž	35	3,4
9689	Splenični limfom robne cone Splenic marginal zone lymphoma	M	4	0,4
		Ž	2	0,2
9591	Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant	M	12	1,2
		Ž	8	0,8
9940	Dlakastocelična levkemija Hairy cell leukaemia	M	3	0,3
		Ž	0	0,0
9671	Limfoplazmatični limfom Lymphoplasmacytic lymphoma	M	7	0,7
		Ž	2	0,2
9761	Waldenströмова makroglobulinemija Waldenström macroglobulinemia	M	2	0,2
		Ž	0	0,0
9732, 9733	Multipli mielom Plasma cell myeloma	M	62	6,1
		Ž	69	6,6
9731, 9734	Solitarni kostni in zunajkostni plazmacitom Solitary plasmacytoma of bone and extraosseous	M	1	0,1
		Ž	5	0,5
9699, nodalni	B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal	M	12	1,2
		Ž	18	1,7
9699, ektranodalni	B-celični limfom robne cone, ektranodalni Marginal zone B-cell lymphoma, extranodal	M	8	0,8
		Ž	13	1,3
9690	Folikularni limfom, BDO Follicular lymphoma, NOS	M	3	0,3
		Ž	2	0,2
9691, 9695	Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2	M	12	1,2
		Ž	23	2,2
9698	Folikularni limfom, gradus 3 Follicular lymphoma, grade 3	M	4	0,4
		Ž	9	0,9
9597	Primarni kožni limfom folikularnih centrov Primary cutaneous follicle centre lymphoma	M	1	0,1
		Ž	0	0,0
9673	Limfom plaščnih celic Mantle cell lymphoma	M	26	2,5
		Ž	10	1,0
9735	Plazmablastni limfom Plasmablastic lymphoma	M	1	0,1
		Ž	1	0,1
9680, 9684	Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL CŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni primer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma	M	59	5,8
		Ž	74	7,1

Tabela 10: Nadaljevanje.

Table 10: Continued.

Šifra ICD-O-3 ICD-O-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
9687, 9826	Burkittov limfom / levkemija Burkitt lymphoma / leukaemia	M	10	1,0
		Ž	2	0,2
9679	Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma	M	2	0,2
		Ž	2	0,2
	Neoplazme zrelih celic T/NK Mature T- and NK-cell neoplasms	M	21	2,1
		Ž	19	1,8
9827, 9831, 9834, 9948	Levkične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms	M	1	0,1
		Ž	2	0,2
9831	Levkična velikih granuliranih limfocitov T T-cell large granular lymphocytic leukemia	M	1	0,1
		Ž	2	0,2
9700, 9701, 9708, 9709, 9716–9719	Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms	M	4	0,4
		Ž	4	0,4
9700	Fungoidna mikoza Mycosis fungoides	M	1	0,1
		Ž	2	0,2
9718	Primarne kožne CD30+ T-celične limfoproliferativne bolezni Primary cutaneous CD30+ T-cell lymphoproliferative disorder	M	1	0,1
		Ž	2	0,2
9709	Primarni kožni periferni limfomi T, redki tipi Primary cutaneous T-cell lymphoma, rare types	M	2	0,2
		Ž	0	0,0
9702, 9705, 9714	Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms	M	16	1,6
		Ž	13	1,3
9702	Periferni limfom T (BD0- in ALK-negativni ALCL) Peripheral T-cell lymphoma (NOS and ALK negative ALCL)	M	11	1,1
		Ž	6	0,6
9705	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	M	1	0,1
		Ž	1	0,1
9714	Anaplastični velikocelični limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive	M	4	0,4
		Ž	6	0,6
9650–9667	Hodgkinov limfom (HL) Hodgkin lymphoma (HL)	M	23	2,3
		Ž	21	2,0
9659	HL z nodularno limfocitno predomnanco Nodular lymphocyte predominant HL	M	2	0,2
		Ž	0	0,0
9650	Klasični HL Classical HL	M	1	0,1
		Ž	4	0,4
9663, 9665, 9667	Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL	M	12	1,2
		Ž	8	0,8
9651	Z limfociti bogat klasični HL Lymphocyte-rich classical HL	M	0	0,0
		Ž	1	0,1
9652	Mešanocelični tip klasičnega HL Mixed cellularity classical HL	M	8	0,8
		Ž	7	0,7
9653	Klasični HL, tip limfocitne deplecije Lymphocyte-depleted classical HL	M	0	0,0
		Ž	1	0,1
9590, 9832	Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukaemia	M	2	0,2
		Ž	3	0,3
9590	Maligni limfom, BD0 Malignant lymphoma, NOS	M	2	0,2
		Ž	3	0,3

Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2013, ki so bili v okviru prvega kurativnega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani.

Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2013, that were treated by primary curative surgery, systemic therapy or radiotherapy during their first treatment.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sistemskim zdravljenjem Number of treated systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število Number	%**
C00–C96	Vse lokacije All sites	13680	11150	81,5	8672	63,4	3876	28,3	2990	21,9
C00–C14	Usta in žrelo Mouth and pharynx	339	314	92,6	169	49,9	27	8,0	247	72,9
C15	Požiralnik Oesophagus	76	39	51,3	17	22,4	21	27,6	27	35,5
C16	Želodec Stomach	475	294	61,9	232	48,8	133	28,0	92	19,4
C18	Debelo črevo Colon	786	683	86,9	670	85,2	185	23,5	7	—
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	587	494	84,2	444	75,6	185	31,5	196	33,4
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	186	42	22,6	15	8,1	26	14,0	2	—
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	176	75	42,6	69	39,2	7	—	2	—
C25	Trebušna slinavka Pancreas	349	111	31,8	71	20,3	64	18,3	5	—
C32	Grlo Larynx	101	90	89,1	44	43,6	1	—	81	80,2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1289	910	70,6	237	18,4	449	34,8	577	44,8
C43	Maligni melanom kože Malignant melanoma of skin	524	516	98,5	515	98,3	3	—	24	4,6
C44	Druge maligne neoplazme kože Skin, other malignomas	2686	2627	97,8	2513	93,6	27	1,0	86	3,2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	71	66	93,0	57	80,3	21	29,6	27	38,0
C50	Dojka Breast	1263	1232	97,5	1095	86,7	1149	91,0	786	62,2
C53	Maternični vrat Cervix uteri	124	116	93,5	94	75,8	6	—	69	55,6
C54	Maternično telo Corpus uteri	311	294	94,5	279	89,7	28	9,0	87	28,0
C56	Jajčnik Ovary	177	148	83,6	134	75,7	118	66,7	3	—
C61	Prostata Prostate	1479	1139	77,0	763	51,6	427	28,9	121	8,2
C62	Modo Testis	96	96	100	94	97,9	50	52,1	2	—
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	407	326	80,1	308	75,7	33	8,1	12	—
C67	Sečni mehur Bladder	344	304	88,4	300	87,2	38	11,0	21	6,1
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	165	131	79,4	121	73,3	65	39,4	98	59,4
C73	Ščitnica Thyroid gland	160	155	96,9	150	93,8	145	90,6	119	74,4
C81	Hodgkinova bolezen Hodgkin's disease	44	38	86,4	1	—	38	86,4	21	47,7
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	374	279	74,6	48	12,8	217	58,0	117	31,3
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	137	112	81,8	7	—	105	76,6	33	24,1
C91–C95	Levkemije Leukaemias	260	145	55,8	4	—	138	53,1	7	—

* Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko zdravljenje ali obsevanje)

* Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15

** Percentages are not calculated for less than 15 cases

Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2013, ki so bili v okviru prvega kurativnega zdravljenja operirani*, po lokaciji raka in bolnici posega.

Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2013, that were treated by surgery during their first primary curative treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Splošna bolnišnica Trbovlje	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	13680	8672	637	96	289	239	2755	1086	1245	330	334	437	519	53	549	103
C00–C14	Usta in žrelo Mouth and pharynx	339	169	1	0	0	0	107	0	56	3	1	1	0	0	0	0
C15	Požiralnik Oesophagus	76	17	0	1	0	0	12	0	4	0	0	0	0	0	0	0
C16	Želodec Stomach	475	232	5	1	10	7	108	0	87	4	4	1	4	0	0	1
C18	Debelo črevo Colon	786	670	58	0	70	42	188	24	95	36	39	36	26	16	27	13
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	587	444	20	1	23	23	119	66	63	29	8	24	19	22	18	9
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	186	15	0	0	0	0	9	0	6	0	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	176	69	1	0	4	3	30	0	24	0	3	2	0	0	1	1
C25	Trebušna slinavka Pancreas	349	71	0	0	0	4	48	0	19	0	0	0	0	0	0	0
C32	Grlo Larynx	101	44	0	0	0	0	28	0	16	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1289	237	0	83	0	0	99	2	52	0	0	0	0	0	0	1
C43	Maligni melanom kože Malignant melanoma of skin	524	515	47	0	36	20	170	30	43	14	8	33	13	7	77	17
C44	Druge maligne neoplazme kože Skin, other malignomas	2686	2513	223	0	131	69	871	23	193	148	106	221	95	3	422	8
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	71	57	2	0	0	1	10	30	5	3	4	0	0	0	1	1
C50	Dojka Breast	1263	1095	15	0	0	15	0	722	215	4	72	2	49	0	0	1
C53	Maternični vrat Cervix uteri	124	94	6	0	1	1	51	3	13	3	1	2	2	1	0	10
C54	Maternično telo Corpus uteri	311	279	31	0	5	9	90	30	48	12	9	12	6	3	0	24
C56	Jajčnik Ovary	177	134	7	0	4	5	60	18	23	1	2	7	3	0	0	4
C61	Prostata Prostate	1479	763	159	0	1	12	173	0	77	39	42	20	237	0	0	3
C62	Modo Testis	96	94	14	0	0	4	37	0	12	4	2	11	9	0	0	1
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	407	308	20	0	0	6	138	2	55	11	17	26	32	0	0	1
C67	Sečni mehur Bladder	344	300	16	0	0	13	144	0	56	13	10	30	18	0	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	165	121	0	0	0	0	95	0	26	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	160	150	3	6	0	3	27	98	11	0	0	0	0	0	0	2
C81	Hodgkinova bolezen Hodgkin's disease	44	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	374	48	2	1	1	0	24	4	10	1	1	2	1	0	1	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	137	7	0	0	0	0	6	0	1	0	0	0	0	0	0	0
C91–C95	Levkemije Leukaemias	260	4	0	0	0	0	4	0	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

* Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

** Less than 30 patients were treated by surgery in individual institution

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2013, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po lokacijah raka in bolnici posega.

Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2013, that were treated by systemic therapy during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemsko terapijo Number of treated systemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ustanova izven RS Institution outside the RS	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	13680	3876	81	141	24	429	2396	453	51	95	42	95	49	10	10
C00–C14	Usta in žrelo Mouth and pharynx	339	27	0	0	0	0	27	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	76	21	0	0	0	1	20	0	0	0	0	0	0	0	0
C16	Želodec Stomach	475	133	2	2	0	20	92	16	0	0	0	0	0	1	0
C18	Debelo črevo Colon	786	185	1	0	0	0	172	5	0	1	0	5	0	1	0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	587	185	0	0	0	2	180	0	0	1	0	1	0	0	1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	186	26	0	0	0	17	3	4	1	0	1	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	176	7	0	0	0	2	3	2	0	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	349	64	1	0	0	14	33	16	0	0	0	0	0	0	0
C32	Grlo Larynx	101	1	0	0	0	0	1	0	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1289	449	0	115	0	0	272	56	1	0	0	0	0	3	2
C43	Maligni melanom kože Malignant melanoma of skin	524	3	0	0	0	0	3	0	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	2686	27	3	0	0	3	3	7	0	0	0	1	8	0	2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	71	21	0	0	0	0	19	2	0	0	0	0	0	0	0
C50	Dojka Breast	1263	1149	7	0	8	0	809	234	0	49	0	39	0	1	2
C53	Maternični vrat Cervix uteri	124	6	0	0	0	0	5	1	0	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	311	28	0	0	0	0	21	7	0	0	0	0	0	0	0
C56	Jajčnik Ovary	177	118	0	0	0	0	91	26	0	1	0	0	0	0	0
C61	Prostata Prostate	1479	427	33	0	10	91	74	41	39	28	28	40	41	0	2
C62	Modo Testis	96	50	0	0	0	0	49	0	0	0	0	0	0	1	0
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	407	33	1	0	0	3	28	0	0	0	1	0	0	0	0
C67	Sečni mehur Bladder	344	38	0	0	0	2	32	0	1	0	0	3	0	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	165	65	0	0	0	8	57	0	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	160	145	3	6	2	21	104	7	0	0	0	0	0	2	0
C81	Hodgkinova bolezen Hodgkin's disease	44	38	0	0	0	7	31	0	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	374	217	4	0	0	23	177	5	0	4	1	2	0	1	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	137	105	14	0	4	56	1	11	4	5	7	3	0	0	0
C91–C95	Levkemije Leukaemias	260	138	10	0	0	106	1	10	2	5	2	1	0	0	1

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less than 10 patients were treated in individual institution

Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2013.

Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2013.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1–4	5–9	10+	Vsi / All
C00	Vse lokacije	M+Ž	11101	31148	24726	32551	94073
C96	All sites	M	5888	16047	11168	11400	41607
		Ž	5213	15101	13558	21151	52466
C00–C14	Usta in žrelo Mouth and pharynx	M	229	525	360	423	1537
		Ž	59	180	166	221	626
C15	Požiralnik Oesophagus	M	36	41	16	19	112
		Ž	7	9	9	7	32
C16	Želodec Stomach	M	207	352	225	350	1134
		Ž	111	215	167	325	818
C18	Debelo črevo Colon	M	352	1354	730	788	3224
		Ž	272	969	694	892	2827
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	327	1075	646	655	2703
		Ž	170	592	528	647	1937
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	57	64	26	14	161
		Ž	19	20	6	8	53
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	36	47	25	26	134
		Ž	47	54	32	27	160
C25	Trebušna slinavka Pancreas	M	76	50	20	13	159
		Ž	70	46	22	16	154
C32	Grlo Larynx	M	72	255	212	320	859
		Ž	15	33	29	52	129
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	498	632	340	325	1795
		Ž	281	390	180	138	989
C43	Maligni melanom kože Malignant melanoma of skin	M	267	787	595	626	2275
		Ž	246	854	798	1092	2990
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1320	3811	2963	3076	11170
		Ž	1307	3969	3373	3884	12533
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	28	64	68	165	325
		Ž	35	84	75	191	385
C50	Dojka Breast	M	12	37	15	33	97
		Ž	1218	4141	3932	6001	15292
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—
		Ž	113	385	562	2486	3546
C54	Maternično telo Corpus uteri	M	—	—	—	—	—
		Ž	297	991	967	2092	4347
C56	Jajčnik Ovary	M	—	—	—	—	—
		Ž	145	333	296	820	1594
C61	Prostata Prostate	M	1401	4689	2931	1253	10274
		Ž	—	—	—	—	—
C62	Modo Testis	M	96	395	461	1169	2121
		Ž	—	—	—	—	—
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	202	593	466	464	1725
		Ž	116	266	278	363	1023
C67	Sečni mehur Bladder	M	199	493	340	330	1362
		Ž	73	135	109	132	449
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	62	81	66	176	385
		Ž	45	65	56	131	297
C73	Ščitnica Thyroid gland	M	41	137	112	177	467
		Ž	111	415	518	700	1744
C81	Hodgkinova bolezen Hodgkin's disease	M	20	86	100	312	518
		Ž	20	90	74	292	476
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	156	436	274	432	1298
		Ž	162	417	345	429	1353
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	42	134	66	28	270
		Ž	57	115	62	29	263
C91–C95	Levkemije Leukaemias	M	103	281	208	311	903
		Ž	72	209	154	294	729

* Pri posameznih lokacijah je pri prikazu prevalence oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 13: Umrljivost* za rakom po lokaciji, spolu in starosti, Slovenija 2013.

Table 13: Cancer mortality* by site, by sex and by age, Slovenia 2013.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C00 – C97	Vse lokacije All sites	M+Ž	6071	3	1	3	2	5	6	9	45	55	132	253	502	657	662	817	983	1936	
		M	3392	2	0	1	1	2	4	4	20	24	65	148	304	410	446	510	566	885	
		Ž	2679	1	1	2	1	3	2	5	25	31	67	105	198	247	216	307	417	1051	
C00	Ustnica Lip	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
C01	Baza jezika Base of tongue	M	7	0	0	0	0	0	0	0	0	1	0	1	2	1	0	0	0	2	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	12	0	0	0	0	0	0	1	1	0	1	1	1	2	1	2	0	2	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
C03	Dlesen Gum	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
C04	Ustno dno Floor of mouth	M	6	0	0	0	0	0	0	0	1	0	1	0	1	0	1	0	0	2	
		Ž	5	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1	1	
C05	Nebo Palate	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C06	Usta, drugi deli Mouth, other & unspecified parts	M	15	0	0	0	0	0	0	0	0	0	0	1	2	3	3	1	3	2	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	
C07	Parotidna žleza Parotid gland	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C09	Tonzila Tonsil	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
C10	Orofarinks Oropharynx	M	44	0	0	0	0	0	0	0	1	1	2	7	8	10	6	4	3	2	
		Ž	9	0	0	0	0	0	0	0	0	1	1	0	1	1	1	1	1	2	
C11	Nazofarinks Nasopharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
C12	Piriformni sinus Pyriform sinus	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C13	Hipofarinks Hypopharynx	M	25	0	0	0	0	0	1	0	0	0	3	4	4	5	5	2	1	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	9	0	0	0	0	0	0	0	0	0	0	0	3	2	0	0	3	1	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
C15	Požiralnik Oesophagus	M	62	0	0	0	0	0	0	0	0	0	3	5	7	6	7	14	10	10	
		Ž	24	0	0	0	0	0	0	0	0	0	0	1	3	1	3	4	3	9	
C16	Želodec Stomach	M	208	0	0	0	0	0	0	0	2	4	5	9	13	18	24	42	37	54	
		Ž	142	0	0	0	0	0	0	1	1	0	4	9	12	12	8	9	27	59	
C17	Tanko črevo Small intestine	M	10	0	0	0	0	0	0	0	0	1	0	0	0	1	0	6	1	1	
		Ž	13	0	0	0	0	0	0	0	1	0	0	1	1	0	0	3	2	5	
C18	Debelo črevo Colon	M	270	0	0	0	0	0	0	0	3	2	4	7	15	32	35	38	56	78	
		Ž	213	0	0	0	0	1	1	0	1	3	6	9	11	11	5	26	42	97	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	39	0	0	0	0	0	0	0	0	0	1	2	3	5	4	5	7	12	
		Ž	25	0	0	0	0	0	0	0	0	1	1	0	0	4	3	1	4	11	
C20	Rektum Rectum	M	159	0	0	0	0	0	0	0	2	1	3	12	17	18	20	24	16	46	
		Ž	89	0	0	0	0	0	0	0	0	2	1	2	6	8	5	7	22	36	
C21	Anus in analni kanal Anus and anal canal	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	171	0	0	0	0	0	0	0	0	0	0	5	25	32	30	26	26	27	
		Ž	80	0	0	0	0	0	0	0	0	1	1	2	2	9	6	11	18	30	
C23	Žolčnik Gallbladder	M	21	0	0	0	0	0	0	0	0	0	1	0	0	2	2	5	3	8	
		Ž	37	0	0	0	0	0	0	0	0	0	0	0	3	2	2	6	8	16	
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	30	0	0	0	0	0	0	0	0	0	0	2	0	3	2	2	10	11	
		Ž	29	0	0	0	0	0	0	0	0	1	0	0	1	4	1	3	4	15	
C25	Trebušna slinavka Pancreas	M	175	0	0	0	0	0	0	0	0	2	2	8	16	22	22	25	25	53	
		Ž	181	0	0	0	0	0	0	0	1	2	3	3	8	23	12	32	35	62	
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	
		Ž	15	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	2	10	
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
C31	Obnosni sinusi Accessory sinuses	M	4	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	1	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
C32	Grlo Larynx	M	55	0	0	0	0	0	0	0	0	0	2	4	7	7	13	10	2	10	
		Ž	12	0	0	0	0	0	0	0	0	0	0	1	4	3	1	2	0	1	
C33	Sapnik Trachea	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C34	Sapnica in pljuča Bronchus and lung	M	748	0	0	0	0	0	0	0	0	1	15	35	101	126	119	116	115	120
		Ž	340	0	0	0	0	1	0	0	0	3	9	23	56	45	47	33	39	84
C37	Timus Thymus	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	8	0	0	0	0	0	0	0	1	0	0	0	2	1	0	2	1	1
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	5
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	5	0	0	0	1	0	0	0	1	0	1	1	0	0	0	0	1	0
		Ž	5	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	1	2
C43	Maligni melanom kože Malignant melanoma of skin	M	67	0	0	0	0	0	0	2	0	1	2	6	8	10	8	10	10	10
		Ž	62	0	0	0	0	0	0	0	4	3	0	2	1	9	2	11	7	23
C44	Druge maligne neoplazme kože Skin, other malignomas	M	18	0	0	0	0	0	0	0	1	0	1	0	0	1	0	3	2	10
		Ž	17	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3	12
C45	Mezoteliom Mesothelioma	M	27	0	0	0	0	0	0	0	1	0	0	0	2	6	6	4	4	4
		Ž	9	0	0	0	0	0	0	0	0	1	0	0	0	0	3	1	2	2
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje Peripheral and autonomic nervous system	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	4	3
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	8	1	0	0	0	0	0	0	0	0	0	0	0	1	2	2	2	0
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	1	0	2	1	0	2
C50	Dojka Breast	M	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2
		Ž	410	0	0	0	0	0	0	3	6	4	20	15	30	39	36	44	49	164
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	27	0	0	0	0	0	0	0	0	0	0	0	0	2	2	6	1	16
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	41	0	0	0	0	0	1	0	0	0	1	5	5	6	4	7	5	7
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	61	0	0	0	0	0	0	0	0	0	0	1	4	0	3	9	20	24
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	47	0	0	0	0	0	0	0	1	0	1	3	3	2	5	6	6	20
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	146	0	0	0	1	0	0	0	4	2	11	13	13	19	12	14	16	41
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	3
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis Penis	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	371	0	0	0	0	0	0	0	0	0	2	2	8	17	35	52	85	170
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C62	Modo Testis	M	8	0	0	0	0	0	0	0	0	2	1	0	1	2	0	1	1	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	119	0	0	0	0	0	0	0	0	1	2	2	13	14	18	23	12	34
		Ž	56	0	0	0	0	0	0	0	0	1	0	1	1	3	6	4	7	33
C65	Ledvični meh Renal pelvis	M	8	0	0	0	0	0	0	0	0	0	0	2	0	1	2	0	1	2
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1
C66	Sečevod Ureter	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C67	Sečni mehur Bladder	M	129	0	0	0	0	0	0	0	0	0	0	3	4	12	15	17	24	54
		Ž	51	0	0	0	0	0	0	0	0	0	0	1	2	4	3	8	6	27
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C69	Oko in očesni adneksi Eye and adnexa	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0

Nadaljevanje —>

Continued —>

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C70	Meninge Meninges	M Ž	1 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0
C71	Možgani Brain	M Ž	63 87	0 1	0 0	0 2	0 0	0 1	2 0	0 1	3 1	3 4	2 3	6 4	6 9	9 10	8 12	6 6	10 19	8 14
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M Ž	0 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
C73	Ščitnica Thyroid gland	M Ž	7 6	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	1 0	1 0	0 0	0 0	0 0	2 0	1 2	2 3
C74	Nadledvična žleza Adrenal gland	M Ž	5 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	0 0	1 0	2 0	0 0	0 0	0 0	0 0	0 2
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M Ž	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M Ž	5 12	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	0 0	1 1	0 1	0 0	2 1	1 8
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M Ž	3 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	2 0	0 0	0 0	0 0	0 0
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M Ž	22 33	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 1	1 4	3 3	1 1	7 5	8 18
C79	Metastaze, drugje Metastases of other sites	M Ž	7 6	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	0 0	1 1	1 0	0 0	2 2
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M Ž	39 42	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	3 0	4 0	7 2	4 1	4 9	5 6	11 24
C81	Hodgkinova bolezen Hodgkin's disease	M Ž	5 4	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	0 0	0 0	0 0	1 0	0 0	0 0	0 1	1 0	2 2
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M Ž	4 8	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 2	0 1	0 0	1 0	0 2	0 1	2 2
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M Ž	21 17	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	1 0	1 1	3 0	3 1	1 2	3 4	8 9
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M Ž	9 5	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 1	1 0	1 0	0 0	1 0	1 0	2 0	2 4
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M Ž	37 43	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	3 0	4 1	3 2	2 1	6 6	8 8	9 25
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M Ž	0 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 2
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M Ž	57 52	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	1 1	3 2	9 2	6 4	11 6	3 4	10 12	14 20
C91	Limfatična levkemija Lymphoid leukaemia	M Ž	54 38	0 0	0 0	1 0	0 0	0 0	1 0	0 0	0 0	0 0	2 0	2 1	1 1	5 3	5 0	9 6	8 6	20 21
C92	Mieločna levkemija Myeloid leukaemia	M Ž	56 32	0 0	0 0	0 0	0 0	1 0	0 0	1 0	0 2	0 0	4 0	3 0	1 3	4 1	9 2	12 5	9 7	12 12
C93	Monocitna levkemija Monocytic leukaemia	M Ž	1 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 2	0 0	0 0	1 0	0 1
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M Ž	2 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	1 0	0 0	0 1
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M Ž	5 7	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 2	1 1	0 0	2 3
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega in sorodnega tkiva Other & unspecified malignant neoplasms of lymphoid, haemopoietic & related tissues	M Ž	33 27	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 0	1 2	1 1	2 1	4 1	10 0	14 21
C97	Maligne neoplazme na več neodvisnih (primarnih) mestih Malignant neoplasms of independant (primary) multiple sites	M Ž	84 43	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 1	0 0	1 0	0 1	5 1	3 4	12 2	17 7	17 5	28 22
Zgoraj neupoštevani Not included above																				
D32	Meninge, benigna neoplazma Benign neoplasm of meninges	M Ž	3 8	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	1 0	1 0	0 0	1 2	0 4
D33	CŽS, benigna neoplazma Benign neoplasm of brain and other parts of CNS	M Ž	1 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 2
D43	CŽS, neopredeljeno CNS, uncertain or unknown	M Ž	3 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	3 0	0 1

* Vir: Nacionalni inštitut za javno zdravje

* Source: National Institute of Public Health

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2011

- Anttila A, Bielska-Lasota M, Davidson T, Van Delden JJ, Von Karsa L, Primic-Žakelj M, et al. Determinants for a successful implementation of population-based cancer screening programmes. Brussels: European Science Advisory Network for Health, 2011.
- Bosetti C, Scelo G, Chuang SC, Tonita JM, Tamaro S, Pompe-Kirn V, et al. High constant incidence rates of second primary cancers of the head and neck: a pooled analysis of 13 cancer registries. *Int J Cancer* 2011;129(1):173–9.
- Buzeti T, Djomba JK, Tomšič S, Gabrijelčič Blenkuš M, Ivanuša M, Zadnik V, et al. Neenakosti v zdravju v Sloveniji. Health inequalities in Slovenia. Ljubljana: Inštitut za varovanje zdravja, 2011.
- Gatta G, Van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Primic-Žakelj M, et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011; 47(17): 2493–511.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Pomen triažnega testa HPV. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 26–39.
- Kadivec M, Krajc M. Rezultati in kazalniki uspešnosti programa DORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 40–8.
- Krajc M. Prednosti in omejitve mamografskega presejanja. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 49–58.
- Krajc M. Epidemiologija raka dojk. In: Mamografska šola, 9. in 10. junij 2012. Ljubljana: Onkološki inštitut, SZD, Združenje radiologov Slovenije, 2011: 1–6.
- Krajc M. Kazalci kakovosti presejalnega programa za raka dojk. In: Farkaš-Lainščak J, ed. Z dokazi podprto javno zdravje: zbornik prispevkov. Ljubljana: Medicinska fakulteta, Katedra za javno zdravje, 2011: str 128.
- Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Second malignancies after childhood noncentral nervous system solid cancer: Results from 13 cancer registries. *Int J Cancer* 2011;129(8):1940–52.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 7–12.
- Primic-Žakelj M. Epidemiologija raka in stopnja preživetja v Sloveniji v populaciji do 39 let. In: Ribič-Pucelj M, ed. Ohranjanje plodne sposobnosti pri onkoloških bolnicah in bolnikih: zbornik. Ljubljana: Slovensko društvo za reproduktivno medicino, 2011: 1–4.
- Primic-Žakelj M, Ivanuš U. Presejanje za raka pri ženskah. In: Čeh A, ed. Presejalni testi pri ženskah in otrocih: zbornik predavanj z recenzijo. Ljubljana: Zbornica zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, Sekcija medicinskih sester – babic, 2011: 7–15.
- Primic-Žakelj M, Ivanuš U. Rezultati in kazalniki uspešnosti programa ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 13–7.

- Primic-Žakelj M, Ivanuš U. Državni program ZORA v letih 2005-2010. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M, eds. 2. izobraževalni dan programa ZORA, Brdo pri Kranju, 8. april 2012. Zbornik. Ljubljana: Onkološki inštitut Ljubljana, 2011: 9–12.
- Primic-Žakelj M, Zadnik V. Epidemiologija raka sečnega mehurja = Epidemiology of bladder cancer. In: Zupančič M, ed. Rak sečnega mehurja: zbornik predavanj. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec, 2010: 7–12.
- Rotovnik Kozjek N, Kompan L, Soeters P, Oblak I, Mlakar Mastnak D, Zadnik V, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. Clin Nutr 2011; 30(5): 567–70.
- Uršič-Vrščaj M, Primic-Žakelj M, Ivanuš U. Novosti v programu ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 18–25.
- Velenik V, Štrbac D, Maučec Zakotnik J, Zadnik V. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. Eur J Cancer 2011; 47(Suppl1): S267.
- Zadnik V, Ivanuš U, Primic-Žakelj M. Geografska analiza incidence raka v Beli krajini in okolici: ugotavljanje morebitnega presežka incidence raka zaradi izpostavljenosti PCB-jem: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Ivanuš U, Primic-Žakelj M. Pojavljanje raka v upravnih enotah Celje in Šentjur pri Celju: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Kovše K, Tomšič S, Primic-Žakelj M. Breme raka v občini Dolenjske Toplice: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Primic-Žakelj M. SLORA - spletna stran z epidemiološkimi podatki o raku. Onkologija 2011; 15(1): 61–3.
- Zadnik V, Primic-Žakelj M. Breme raka uroloških in reproduktivnih organov v Sloveniji. Slov 2000 in rak 2011; 8–12.
- Žagar T, Zadnik V, Primic-Žakelj M. Local standardized incidence ratio estimates and comparison with other mapping methods for small geographical areas using Slovenian breast cancer data. Journal of Applied Statistics 2011; 38(12): 2751–61.

2012

- Čuić M, Zadnik V. Prekomerna telesna teža in debelost kot dejavnik tveganja raka = Overweight and obesity as cancer risk factor. In: Babnik K, Kocbek M, eds. Slovenski dan dietetike: prva znanstvena konferenca z mednarodno udeležbo, Izola, 25. oktober 2012. Zbornik prispevkov. Koper: Založba Univerze na Primorskem, 2012: 63–8.
- Glumac N, Hočevar M, Zadnik V, Snoj M. Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma. Radiol Oncol 2012; 46(3): 258–64.
- Gregorič B, Zadnik V, Jezeršek Novaković B. The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. Radiol Oncol 2012; 46(2): 153–9.
- Ivanuš U, Primic-Žakelj M. Interlaboratory variability in HPV-positive rates in ASC-US/LSIL smears in the cervical cancer screening programme ZORA = Razlike med citološkimi laboratoriji v deležu HPV-pozitivnih izvidov APC-N/PIL-NS v presejalnem programu za raka materničnega vratu ZORA. In: Strojan Fležar M, Luzar B, Gutnik H, Pižem J, Kocjan G, eds. Novosti v citopatologiji: most med kliniko in diagnostično patologijo: Bridge between clinics and diagnostic pathology. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2012: 203–8.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Aktivnosti DP ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. Zbornik. Ljubljana: Onkološki inštitut, 2012: 53–63.
- Ivanuš U, Primic-Žakelj M. Samoodvzem vaginalnega vzorca za test HPV pri neodzivnicah presejalnih programov raka materničnega vratu. Onkologija 2012; 16(2): 78–86.
- Ivanuš U, Primic-Žakelj M. Tretji izobraževalni dan programa ZORA. Onkologija 2012; 16(2): 98–100.
- Jarm K. Podrobna raziskava preživetja bolnikov z rakom danke v Sloveniji, zbolelih v letih 2003-2005: specialistična naloga s področja javnega zdravja. Ljubljana: Onkološki inštitut; 2012.

- Koivisto-Korander R, Scélo G, Ferro G, Mellekjær L, Hemminki K, Pompe-Kirn V, et al. Second primary malignancies among women with uterine sarcoma. *Gynecol Oncol* 2012; 126(1): 30–5.
- Kovač V, Zwitter M, Žagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. *Radiol Oncol* 2012; 46(2): 136–44.
- Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Primic-Žakelj M, et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. *Breast Cancer Res Treat* 2012; 134(1): 363–70.
- Primic-Žakelj M, Ivanuš U. Aktivnosti DP ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. Zbornik. Ljubljana: Onkološki inštitut, 2012: 9–14.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Rak pri starostniku. Ljubljana: Onkološki inštitut, 2012: 14–25.
- Primic-Žakelj M, Žagar T. Razširjenost, preprečevanje in zgodnje odkrivanje pljučnega raka. In: Matković M, ed. Pacienti in pljučni rak – trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege Slovenije – Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2012: 19–31.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. *Slov 2000 Rak* 2012: 6–9.
- Primic-Žakelj M. Razširjenost in pomen redkih rakavih bolezni. In: Primic-Žakelj M, ed. Redki raki. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 7–13.
- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Fležar MS. Review of negative and low-grade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. *Cytopathol Off J Br Soc Clin Cytol* 2012; 23(1): 23–9.
- Uršič-Vrščaj M, Ivanuš U. HPV testiranje. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj, Ljubljana, marec 2012. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2012: 63–9.
- Zadnik V, Primic-Žakelj M. Epidemiologic data on cervical cancer. In: Takač I, ed. Recent advances in cervical cancer. Kerala: Transworld Research Network, 2012: 1–7.
- Zadnik V, Primic-Žakelj M, Krajc M. Breme raka v Sloveniji v primerjavi z drugimi evropskimi državami = Cancer burden in Slovenia in comparison with the burden in other European countries. *Zdr Vestn* 2012; 81(5): 407–12.
- Zadnik V, Žagar T, Primic-Žakelj M. Analiza vpliva točkovnih virov onesnaženja na zbolevanje za rakom v Zasavju = Analysis of the impact of point source pollution on cancer in Zasavje. In: Kraigher A, ed. Zbornik predstavitev. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1.
- Žagar T, Primic-Žakelj M, Zadnik V. Slovenian maps of local standardized incidence ratio. In: 34th International Association of Cancer Registries Conference, 17–19 September 2012. Cork: The National Cancer Registry, 2012: 42.
- Žagar T, Zadnik V, Primic-Žakelj M. Možnosti raziskovanja vpliva bivalnega okolja na pojavljanje raka. In: Kraigher A, ed. Zbornik predstavitev. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1–15.
- Žist A, Milanez T, Škrbinc B, Zadnik V, Šeruga B. Spregledana korist neoadjuvantne kemoterapije v zdravljenju mišično invazivnega raka sečnega mehurja. *Onkologija* 2012; 16(2): 74–7.

2013

- Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Primic-Žakelj M, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. *International journal of cancer* 2013; 132: 1170–81.
- Gašljevič G, Lamovec J, Contreras JA, Zadnik V, Blas M, Gašparov S. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental FISH study. *Pathol Oncol Res* 2013; 19: 855–65.
- Ivanuš U, Primic-Žakelj M, Žagar T, Florjančič M, Kuster M. Delovanje državnega presejalnega programa za raka materničnega vratu ZORA v osrednjeslovenski statistični regiji. In: Letnar Žbogar N, et al. Zdravje v ljubljanski zdravstveni regiji 2012. Ljubljana: Zavod za zdravstveno varstvo, 2013: 74–94.
- Ivanuš U, Primic-Žakelj M. Klinična uporaba in pomen testa za humani papilomski virus v Državnem presejalnem programu ZORA (Clinical use and value of human papillomavirus test in national cervical cancer screening programme ZORA). *Med Razgl* 2013; 52(3): 123–35.
- Ivanuš U, Primic-Žakelj M. Pomen izvida testa HPV v kolposkopski ambulanti. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2013: 78–101.

- Ivanuš U, Primic-Žakelj M. Uporaba triaznega testa HPV v programu ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2013: 27–34.
- von Karsa L, Maučec-Zakotnik J, Primic-Žakelj M et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. *Endoscopy* 2013; 45, 51–9.
- Koželj M, Zver S, Zadnik V. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. *Radiol Oncol* 2013; 47: 161–5.
- Krajc M, Šval C, Kadivec M, Hertl K, Primic-Žakelj M. Rezultati državnega presejalnega programa Dora v ljubljanski regiji. In: Letnar Žbogar N, et al. Zdravje v ljubljanski zdravstveni regiji 2012. Ljubljana: Zavod za zdravstveno varstvo, 2013: 66–73.
- Maver Vodičar P, Seme K, Korač T, Dimitrov G, Döbrössy L, Primic-Žakelj M, et al. Cervical cancer screening practices in central and eastern Europe in 2012. *Acta Dermatovenerol APA* 2013; 22: 7–19.
- Primic-Žakelj M, Ivanuš U. Deset let delovanja programa ZORA. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2013: 7–11.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega črevesa in danke. In: Šola tumorjev prebavil, Ljubljana, 30. 11. 2012. Ljubljana: Onkološki inštitut, 2013: 17–20.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka prostate, sečnega mehurja, ledvic in mod v Sloveniji. In: Novaković S, ed. Izzivi v multidisciplinarni obravnavi bolnikov z rakom sečnega mehurja, prostate, ledvic in mod. Zbornik. Ljubljana: Onkološki inštitut: Kancerološko združenje Slovenskega zdravniškega društva, 2013: 16–23.
- Primic-Žakelj M. Epidemiology of cancer diseases in different European regions and the importance of risk factors. In: Fourth International Medical Congress, 11-15 September 2013, Portorož, Slovenia, 2013: 49–51.
- Primic-Žakelj M, Ivanuš U, Žagar T. Neodzivnice DP DORA so bolj ogrožene z rakom materničnega vratu (Non-responders to the National Cervical Cancer Screening Programme Zora are at an increased risk of cervical cancer). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvodkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 29.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak dojke: zbolewnost, preživetje in dejavniki tveganja. In: Matković M, ed. Pacientke z rakom dojke - trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2013: 5–13.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. In: Novosti v diagnostiki in zdravljenju raka, Ljubljana, 13. decembra 2013: ob jubilejni, 20. obletnici delovanja združenja Fundacija doc. dr. Josip Cholewa v sodelovanju z Medicinsko fakulteto Ljubljana, Kliničnim centrom Ljubljana in Onkološkim inštitutom Ljubljana. Ljubljana: Fundacija doc. dr. Josip Cholewa, 2013: 5–6.
- Zadnik V, Žagar T, Jarm K, Primic-Žakelj M. The evaluation of the mesothelioma epidemic in Slovenia. In: 35th International Association of Cancer Registries Conference, 22-24 October 2013, Buenos Aires. Programme & abstracts. Buenos Aires: The National Cancer Institute, 2013: 109.
- Zadnik V, Ivanuš U, Žagar T, Primic-Žakelj M. Pojavljanje raka na območju upravnih enot Celje in Šentjur pri Celju (Cancer incidence in administrative units Celje and Šentjur pri Celju). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvodkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 74.
- Znaor A, van den Hurk C, Primic-Žakelj M, Agius D, Coza D, Demetriou A, et al. Cancer incidence and mortality patterns in South Eastern Europe in the last decade : gaps persist compared with the rest of Europe. *Eur J Cancer* 2013; 49: 1683–91.
- Žagar T, Zadnik V, Primic-Žakelj M. Local estimation of standardized incidence ratio applied to Slovenian cancer data. V: International Conference Applied Statistics 2013, September 22-25, 2013, Ribno (Bled), Slovenia. Lusa L, Stare J, eds. Abstracts and program. Ljubljana: Statistical Society of Slovenia, 2013: 55.
- Žagar T, Primic-Žakelj M, Zadnik V. Zemljevidi raka, narejeni z metodo lokalno ocenjenega standardiziranega količnika (Cancer maps created with local standardized incidence ratio method). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvodkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 71.

2014

- Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Primic-Žakelj M, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. *J Eur Acad Dermatol Venereol* 2014; 28: 1170–8.
- Gutnik H, Matič JP, Primic-Žakelj M, Strojani Fležar M. Microinvasive cervical squamous cell carcinoma in Slovenia during the period 2001–2007. *Radiol Oncol* 2014; 48: 282–8.
- Ivanuš U, Primic-Žakelj M. Učinkovitost triažnega testa HPV pri ženskah s presejalno diagnozo APC-N in rezultati triažnega testiranja na HPV v 2013. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 45–52.
- Ivanuš U, Primic-Žakelj M. Obravnava žensk z indikacijo za triažni test HPV. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 48–69.
- Jarm K, Ivanuš U, Krajc M, Primic-Žakelj M. Državna presejalna programa za raka materničnega vratu in dojke. In: Grmek-Košnik I, Hvalič Touzery S, Skela-Savič B, eds. Kronične bolezni sodobne družbe: od zgodnjega odkrivanja do paliativne oskrbe: zbornik prispevkov z recenzijo. Jesenice: Fakulteta za zdravstvo, 2014: 99–106.
- Kadivec M, Krajc M, Hertl K, Jarm K, Primic-Žakelj M, Šval C. Državni presejalni program za raka dojke Dora - program zgodnjega odkrivanja raka dojke = Slovenian breast cancer screening programme Dora - programme for early breast cancer detection. In: Završnik J, ed. Bolezni dojke: [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 221–8.
- Kloboves-Prevodnik V, Uhan Kastelic S, Pohar-Marinšek Ž, Žagar T, Ivanuš U. Atipične žlezne celice, neopredeljene: rezultati revizije citoloških preparatov in tveganje CIN2+. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 64–72.
- Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešić N et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. *Clinical genetics* 2014; 85: 59–63.
- Krašovec A, Ferjančič M. Povezovanje podatkovne zbirke Registra raka Republike Slovenije z ostalimi zdravstvenimi in upravnimi zbirkami = Linking of the Cancer Registry of the Republic of Slovenia Database with Other Health and Administrative Databases. In: Štemberger Kolnik T, ed. Zdravstvena nega v javnem zdravju = Nursing in public health : druga znanstvena konferenca z mednarodno udeležbo, Izola, 31. januar 2014 = Second scientific conference with international participation. Zbornik prispevkov = Proceedings. Koper: Založba Univerze na Primorskem, 2014: 59–65.
- Pogačnik A, Kloboves-Prevodnik V, Nolde N, Novaković S, Ivanuš U, Primic-Žakelj M, et al. Nove triažne metode pri HPV-pozitivnih ženskah. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 36–40.
- Primic-Žakelj M. Current situation and prospects of cancer in the Balkan area: what can we do together?. In: Book of abstracts = international scientific conference. Tirana: Academy of Sciences of Albania, 2014: 6–7.
- Primic-Žakelj M, Ivanuš U. Državni presejalni program za raka materničnega vratu Zora: zgodba o uspehu. In: Petrovec M, Golle A, eds. Okužbe spolovil in spolno prenosljive bolezni: [zbornik predavanj], (Medicinski razgledi, ISSN 0353-3484, Supplement, letn. 53, 6). Ljubljana: Medicinski razgledi, 2014: 249–55.
- Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP ZORA - 2013/2014. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 7–11.
- Primic-Žakelj M, Ivanuš U. Presejalni programi za raka materničnega vratu - trenutno stanje in prihodnost. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 27–36.
- Primic-Žakelj M, Jarm K, Žagar T. Epidemiološke značilnosti raka prebavil v Sloveniji v zadnjem desetletju. In: Ivanecz A, Krebs B, Potrč S, eds. Simpozij z mednarodno udeležbo na temo Smernice in problemi zdravljenja malignomov želodca, trebušne slinavke in debelega črevesa ter danke. Zbornik predavanj. Maribor: Oddelek za abdominalno in splošno kirurgijo, Kirurška klinika UKC, 2014: 1–4.
- Primic-Žakelj M, Žagar T, Jarm K. Zbolevnost za rakom dojke in preživetje = Breast cancer incidence and survival rate. In: Završnik J, ed. Bolezni dojke [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 115–24.

- Primic-Žakelj M, Žagar T, Zadnik V. Epidemiološke značilnosti malignomov krvotornega in limfatičnega tkiva. In: Primic-Žakelj M ed. XXII. seminar In memoriam dr. Dušana Reje. Malignomi krvotornega in limfatičnega tkiva. Ljubljana: Zveza slovenskih društev za boj proti raku, 2014: 7–34.
- Primic-Žakelj M, Žagar T, Zadnik V, Škrlec F. Linkage of the Slovenian Cancer Registry data to other state databases and to screening registries. In: European Union and European Network of Cancer Registries (ENCR). Towards a harmonised cancer information system in Europe, 2014: 71.
- Strojani P, Zadnik V, Šifer R, Lanišnik B, Didanovič V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983–2009: role of human papillomavirus infection. Eur Arch Otorhinolaryngol 2014: 1–7.
- Šeruga B, Zadnik V, Grašič-Kuhar C, Marinko T, Čufer T, Zakotnik B, et al. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer investigation 2014; 32: 99–104.
- Škrlec F, Šturm N. Pristojnosti diplomirane medicinske sestre s specialnimi znanji iz onkološke epidemiologije v Registru raka Republike Slovenije = Nurse with Special Knowledge in Oncological Epidemiology and His or Her Competences in Cancer Registry of Republic of Slovenia. In: Štemberger Kolnik T, ed. Zdravstvena nega v javnem zdravju = Nursing in public health : druga znanstvena konferenca z mednarodno udeležbo, Izola, 31. Januar 2014 = Second scientific conference with international participation. Zbornik prispevkov = Proceedings. Koper: Založba Univerze na Primorskem, 2014: 83–91.
- Škulj P, Babuder B, Zadnik V. Slora - Slovenija in rak, interaktivni spletni portal = Slora - Slovenia and cancer, an interactive web portal. In: Štemberger Kolnik T, ed. Zdravstvena nega v javnem zdravju = Nursing in public health : druga znanstvena konferenca z mednarodno udeležbo, Izola, 31. Januar 2014 = Second scientific conference with international participation. Zbornik prispevkov = Proceedings. Koper: Založba Univerze na Primorskem, 2014: 67–73.
- Zadnik V. Rak debelega črevesa in danke: epidemiološke značilnosti in nevarnostni dejavniki. In: Ocvirk J, ed. Sodobna obravnava raka debelega črevesa in danke. Ljubljana: Europacolom Slovenija, združenje za boj proti raku debelega črevesa in danke, 2014: 22–4.
- Zadnik V, Žagar T, Primic-Žakelj M. Nizkofrekvenčna polja in rak. In: Gajšek P, ed. Strokovni seminar Daljnovidni in zdravje, Ljubljana, 25. 9. 2014. Zbornik predavanj. Ljubljana: Inštitut za neionizirano sevanja, 2014: 19–21.
- Zanetti R, Sacchetto L, Calvia M, Bordoni A, Hakulinen T, Primic-Žakelj M, et al. Economic evaluation of cancer registration in Europe. J Registry Manag 2014; 41: 31–7.
- Žagar T, Primic-Žakelj M, Zadnik V, Škrlec F, Jarm K. Completeness of the cancer registry of the Republic of Slovenia using qualitative methods. In: International Association of Cancer Registries (IACR), 36th annual conference 2014. Ottawa, Canada, 26–28 June 2014. Ottawa: The National Cancer Institute, 2014: 109.

2015

- Allemani C, Weir HK, Carreira H, Harewood R, Primic-Žakelj M, Žagar T, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385: 977–1010.
- Borrás JM, Barton M, Grau C, Corral J, Verhoeven R, Primic-Žakelj M, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol 2015; 116: 45–50.
- Borrás JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Primic-Žakelj M, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol 2015; 116: 38–44.
- Ivanuš U, Primic-Žakelj M. Test HPV doma za neodzivnice programa Zora: preliminarni rezultati. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana; 2015: 49–55.
- Ivanuš U, Primic-Žakelj M. Vloga triažnega testa HPV in kolposkopije v programu ZORA. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD in Onkološki inštitut, 2015: 35–52.

- Ivanuš U, Učakar V. Okužbam pripisljivi raki in preprečevanje s cepljenjem. In: Novaković S, Zakotnik B, Žgajnar J, eds. Preprečevanje raka: dejstva, ki jih mora vedeti zdravstveni delavec: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2015: 89–102.
- Jarm K, Krajc M, Primic-Žakelj M, Šval C, Purić F, Kadivec M, et al. Presejanje za raka dojke: program Dora. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 70–5.
- Karalexi MA, Papathoma P, Thomopoulos TP, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumour mortality and survival in Southern and Eastern Europe (1983-2014): Gaps persist across 14 cancer registries. *Eur J Cancer* 2015; 51: 2665–77.
- Krajc M, Primic-Žakelj M. Dojenje, hormonska zdravila in drugi dejavniki, vpleteni v nastanek raka dojke. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 77–86.
- Papathoma P, Thomopoulos TP, Karalexi MA, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries. *Eur J Cancer* 2015; 51: 1444–55.
- Primic-Žakelj M. Redke rakave bolezni. In: Modic K, ed. Redke bolezni: 28 februar 2015. Ljubljana: Društvo BKB, 2015: 35–40.
- Primic-Žakelj M. Kaj je evropski kodeks proti raku. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 7–9.
- Primic-Žakelj M, Čeh F. Najpogostejši raki pri moških 2015. Zveza slovenskih društev za boj proti raku, 2015.
- Primic-Žakelj M, Čeh F. 12 nasvetov proti raku : Evropski kodeks proti raku 2014-2015. Zveza slovenskih društev za boj proti raku, 2015.
- Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP Zora - 2014/2015. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 7–10.
- Primic-Žakelj M, Žagar T. Preprečevanje raka v ustni votlini. In: Artnik B, Premik M, Jovanovič K, eds. Zbornik člankov in izvlečkov, Kongres ob 40-letnici strokovnih srečanj stomatologov Slovenije [tudi] 40 srečanje stomatologov Slovenije "Iz prakse za prakso" in pridruženi 10 Cvahtetovi dnevi javnega zdravja "Skrb za ustno zdravje", Portorož, 4 do 6 junij 2015. Ljubljana: Stomatološka sekcija Slovenskega zdravniškega društva, 2015: 22–9.
- Rems M, Jarm K, Zadnik V, Primic-Žakelj M. Lokalna ponovitev bolezni pri bolnikih, operiranih zaradi nemetastatskega raka danke, zbolelih v obdobju 2003-2005 = Local recurrence of rectal cancer in patients with nonmetastatic disease, diagnosed in 2003-2005. *Zdrav vest* 2015; 84: 277–86.
- Sant M, Chirlaque Lopez MD, Agresti R, Sanchez Perez MJ, Hollecsek B, Primic-Žakelj M, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EURO-CARE-5 study. *Eur J Cancer* 2015; 51: 2191–205.
- Sant M, Minicozzi P, Primic-Žakelj M, Otter R, Francisci S, et al. Cancer survival in Europe, 2000–2007: Doing better, feeling worse? *Eur J Cancer* 2015; 51: 2101–3.
- Schuz J, Espina C, Villain P, Herrero R, Leon ME, Primic-Žakelj M, et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. *Cancer epidemiol* 2015; 39 Suppl 1: S1–10.
- Strojman P, Zadnik V, Sifrer R, Lanisnik B, Didanovic V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983-2009: role of human papillomavirus infection. *Eur Arch Otorhinolaryngol* 2015; 272: 3805–14.
- Zadnik V. Epidemiologija raka jajčnika. In: Smrkolj S, Zobec Logar H, Šešek M, eds. Rak jajčnikov: zbornik. Ljubljana: Slovensko zdravniško društvo, Združenje za radioterapijo in onkologijo, 2015: 6–9.
- Zadnik V. Epidemiološki trendi hormonsko odvisnih rakov = Epidemiological trends of hormon related-cancers. In: Černe K, ed. Kemijski povzročitelji hormonskih motenj od molekule do človeka = Endocrine disrupting chemicals - from molecule to man. Ljubljana: Slovensko toksikološko društvo, 2015: 22.
- Zanetti R, Schmidtman I, Sacchetto L, Binder-Foucard F, Bordoni A, Zadnik V, et al. Completeness and timeliness: Cancer registries could/should improve their performance. *European journal of cancer*. 2015; 51: 1091–8.
- Zwitter M, Žagar T. Zdravljenje pljučnega raka: perspektiva dveh desetletij. In: Kovač V, Rajer M, eds. Prva šola pljučnega raka. Ljubljana: Slovensko zdravniško društvo, 2015: 116–20.



POROČILO RR št. 55
REPORT No. 55
Ljubljana 2016
ISSN 1318-5845